Page last updated: 2024-11-03

prazosin and Adenoma, Prostatic

prazosin has been researched along with Adenoma, Prostatic in 268 studies

Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Research Excerpts

ExcerptRelevanceReference
"The present study aims to assess and compare the effects of carvedilol and terazosin plus enalapril on lower urinary tract symptoms (LUTS), the urine flow, and blood pressure (BP) in patients with moderate hypertension (HTN) and benign prostatic hyperplasia (BPH)."9.41A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. ( DalirAkbari, N; Farshi, A; Khalili, M; Mahmoudinezhad, M; Zomorrodi, A, 2021)
" One hundred patients with Benign Prostatic Hyperplasia were randomly divided into 2 equal groups receiving prostafit and prazosin, respectively."9.19Pumpkin seed oil (prostafit) or prazosin? Which one is better in the treatment of symptomatic benign prostatic hyperplasia. ( Mahboob, MR; Masuminia, M; Mohammadi, S; Shirvan, MK, 2014)
"This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension."9.14[Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. ( Fang, J; Li, YL; Liu, HP; Qin, XH; Xu, XP; Yang, C; Zhang, X, 2009)
"Terazosin is an alpha1-selective adrenoceptor blocking agent that has been reported in many clinical trials to be an effective choice for the treatment of benign prostatic hyperplasia (BPH)."9.12Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. ( Lan, SK; Ou, JH; Tsai, YS; Tzai, TS, 2007)
"Finasteride, which inhibits the enzyme 5 alpha-reductase, reduces prostate size and relieves the symptoms of benign prostatic hyperplasia (BPH) in men with enlarged prostates."9.11Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. ( Doggrell, SA, 2004)
"The objective of the present study was to evaluate the efficacy and safety of Prostina, a multi-ingredient herbal formulation in benign prostatic hyperplasia (BPH) in comparison with terazosin."9.11Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia. ( Biswas, NR; Dogra, PN; Kumar, V; Mani, K; Ravi, AK, 2005)
"To review and assess the cardiovascular safety of the alpha1-blocker terazosin when used to treat symptomatic benign prostatic hyperplasia (BPH) in patients taking concurrent antihypertensive medications."9.09Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. ( Lowe, FC; Olson, PJ; Padley, RJ, 1999)
" This result was not significant but suggested a favorable effect of terazosin on diminishing the risk of coronary heart disease."9.09[Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy]. ( Kageyama, S; Tamaki, M; Ueda, T, 1999)
"The objective of this open randomized clinical study was to compare the short-term efficacy and safety of three alpha-1 blockers, prazosin, terazosin and tamsulosin, in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)."9.09Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. ( Tsujii, T, 2000)
"We compared the efficacy of once a day administration of terazosin hydrochloride with that of twice a day administration for benign prostatic hyperplasia (BPH) patients."9.09[A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin]. ( Ikemoto, I; Ohishi, Y; Ohnishi, T; Suzuki, H; Suzuki, Y; Yamazaki, H, 2001)
"To evaluate long-term efficacy and safety of terazosin, a selective alpha 1 blocker, in the treatment of benign prostatic hyperplasia (BPH)."9.08Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. ( Lepor, H, 1995)
"We developed a decision analytic model to compare the costs of treatment for an initial 2-year period with finasteride, terazosin, and transurethral resection of the prostate (TURP) in men with at least moderate symptoms of benign prostatic hyperplasia (BPH)."9.08Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. ( Chmiel, JJ; Hillman, AL; Lowe, FC; McDaniel, RL, 1995)
"This is a controlled efficacy study with doxazosin (4 mg/day) in the long-term management of 64 ambulatory patients with benign prostatic hyperplasia (BPH)."9.08Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One). ( Dutkiewicz, S; Witeska, A, 1995)
"To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha(1)-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH)."9.08The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. ( Deverka, PA; Hillman, AL; Mason, MF; Maurath, CJ; Oesterling, JE; Padley, RJ; Peskin, E; Roehrborn, CG; Schwartz, JS; Willian, MK, 1996)
"We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH)."9.08Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. ( de La Rosette, JJ; de Wildt, MJ; Debruyne, FM; Rosier, FW; van Iersel, MP; Witjes, WP, 1996)
"This study was designed to evaluate the safety and efficacy of the selective alpha 1-adrenoceptor blocker terazosin in the treatment of benign prostatic hyperplasia (BPH)."9.08A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. ( Barkin, J; Beland, G; Boake, RC; Casey, RW; Elhilali, MM; Fradet, Y; Klotz, LH; Orovan, WL; Ramsey, EW; Schick, E; Trachtenberg, J, 1996)
"We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia."9.08The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. ( Barry, MJ; Brawer, MK; Dixon, CM; Gormley, G; Haakenson, C; Lepor, H; Machi, M; Narayan, P; Padley, RJ; Williford, WO, 1996)
"To evaluate the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia (BPH)."9.08The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. ( Debruyne, FM; Fitzpatrick, J; Kirby, R; Kirk, D; Prezioso, D; Witjes, WP, 1996)
"2 mg) of tamsulosin, a selective alpha 1A-adrenoreceptor antagonist, with an increasing dose (1-5 mg) of terazosin, a non-selective antagonist, in the treatment of urinary outflow obstruction associated with benign prostatic hyperplasia (BPH) in Korean patients."9.08Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. ( Lee, C; Lee, E, 1997)
"To determine the effects of terazosin on blood pressure and on antihypertensive therapy when used in managing benign prostatic hyperplasia (BPH)."9.08Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. ( Kirby, RS, 1998)
"To examine the clinical usefulness of selective and non-selective alpha 1-adrenoceptor antagonists, we compared a selective (tamsulosin) and non-selective (terazosin) alpha 1-adrenoceptor antagonists in the treatment of Chinese patients with benign prostatic hyperplasia (BPH)."9.08Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. ( Gu, FL; Guo, YL; Na, YJ, 1998)
"Alfuzosin, a selective alpha 1-adrenoceptor antagonist which is effective in the symptomatic treatment of benign prostatic hyperplasia (BPH), was compared with prazosin, another drug commonly used for the same purpose."9.07Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. ( Blondin, P; Buzelin, JM; Hebert, M, 1993)
"To evaluate the efficacy and tolerability of terazosin, a long-acting selective alpha 1-receptor antagonist, in patients with benign prostatic hyperplasia."9.07Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. ( Adams, G; Brawer, MK; Epstein, H, 1993)
"This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)."9.07Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. ( Lowe, FC, 1994)
"Terazosin is safe and effective in treating concomitant hypertension and BPH."9.07Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial. ( Guthrie, R, 1994)
"This randomised, placebo-controlled, double-blind study was performed to evaluate the efficacy and safety of once-a-day terazosin (10 mg/d) in ambulatory patients (n = 57) with benign prostatic hyperplasia (BPH)."9.07Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. ( Fabricius, PG; Hannaford, JM, 1992)
"The purpose of this multicentre, randomised, placebo-controlled, double-blind study was to verify the safety and efficacy of terazosin, an alpha 1 adrenergic blocker, in patients with benign prostatic hyperplasia (BPH)."9.07Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. ( Di Silverio, F, 1992)
"The primary objective of the present interim analysis of an open label study initiated in December 1988 is to provide further insight into the long-term safety, efficacy and compliance of terazosin, a long-acting selective alpha 1-blocker, for the treatment of symptomatic benign prostatic hyperplasia (BPH)."9.07The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Meretyk, S, 1992)
"Terazosin, a selective, long-acting alpha 1-adrenergic blocker, was evaluated in 44 men with benign prostatic hyperplasia."9.07Efficacy of terazosin in patients with benign prostatic hyperplasia. ( Laddu, A; Matzkin, H; Rangel, MC; Soloway, MS, 1992)
"A series of 93 normotensive patients with benign prostatic hyperplasia and maximum urinary flow rates < 15 ml/s, treated at 2 hospital centres using an identical protocol, was randomly assigned to receive a 12-week course of treatment with prazosin or placebo in a double-blind parallel group trial."9.07A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. ( Abrams, PH; Chapple, CR; Christmas, TJ; Milroy, EJ; Stott, M, 1992)
"This randomized, placebo-controlled, double-blind study was performed to evaluate the efficacy and safety of once-a-day terazosin (10 mg/day) in ambulatory patients (n = 57) with benign prostatic hyperplasia (BPH)."9.06Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. ( Dunzendorfer, U; Fabricius, PG; Hannaford, JM; Maurath, C; Weizert, P, 1990)
"The efficacy and safety of terazosin, a selective long-acting alpha-1-adrenergic blocker, were evaluated in 45 normotensive patients with symptomatic benign prostatic hyperplasia ranging from 50 to 76 years old."9.06A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Sunshine, H, 1990)
"In a double blind cross-over study, the selective alpha 1-adrenoceptor blocker prazosin was given to eleven men with a non-hyperplastic prostate and with symptoms of bladder neck obstruction."9.06Effects of prazosin in men with symptoms of bladder neck obstruction and a non-hyperplastic prostate. ( Andersson, KE; Hedlund, H, 1989)
"The effectiveness and safety of tamsulosin and terazosin for patients with benign prostatic hyperplasia (BPH) was evaluated by literature review."8.85Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. ( Chen, W; Dong, Z; Gao, W; Liu, Y; Wang, Z; Yang, K, 2009)
"To determine the effectiveness of the long-acting alpha(1)-adrenergic receptor blocking agent terazosin compared with placebo on lower urinary tract symptoms and peak urinary flow rate in men with clinical benign prostatic hyperplasia."8.81Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. ( Boyle, P; Manski, R; Padley, RJ; Robertson, C; Roehrborn, CG, 2001)
"Naftopidil, a phenylpiperazine derivative, is a novel alpha 1-adrenoceptor antagonist and is new drug for the bladder outlet obstruction in patients with benign prostatic hyperplasia (BPH)."8.80[Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia]. ( Ikegaki, I, 2000)
"In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia."8.79Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. ( Lowe, FC; McKiernan, JM, 1997)
"Terazosin is a selective alpha 1 adrenoceptor antagonist that is currently under clinical investigation for the treatment of clinical BPH."7.77Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. ( Laddu, A; Lepor, H, 1992)
"To investigate the effects of amlodipine, a dihydropyridine calcium-channel blocker, alone or combined with terazosin, on urodynamics in rats with benign prostatic hyperplasia (BPH) and in female rats with detrusor instability (DI)."7.75Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity. ( Chen, GL; Liu, HP; Liu, P; Xu, XP, 2009)
"The objective of this meta-analysis of randomized controlled trials (RCTs) of terazosin versus placebo in men with benign prostatic hyperplasia (BPH) was to evaluate the effect of terazosin on lower urinary tract symptoms."7.72Effect of terazosin on clinical benign prostatic hyperplasia in older adults. ( Ahmed, A; Mudiyala, R, 2003)
"Thirty-six male patients with symptomatic benign prostatic hyperplasia (BPH) with a serum prostate-specific antigen level of 4-10 ng/mL underwent MRI with body coil, transrectal prostate ultrasonography and biopsy prior to terazosin therapy."7.71Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia. ( Alkibay, T; Ataoglu , O; Atilla, S; Isen, K; Isik, S; Sezer, C; Sinik, Z; Sözen, S, 2001)
"We evaluated the short-term efficacy of terazosin for treating symptomatic benign prostatic hyperplasia (BPH)."7.71The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia. ( Akimoto, M; Horiuchi, K; Suzuki, Y; Tsuboi, N; Yoshida, K, 2001)
"To determine the changes in plasma lipid levels in symptomatic benign prostatic hyperplasia (BPH) patients receiving terazosin treatment."7.71Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia. ( Akbay, E; Bozlu, M; Cayan, S; Doruk, E; Ulusoy, E, 2001)
"Recent evidence indicated that an alpha 1 blocker, doxazosin, induces prostate apoptosis in patients with benign prostatic hyperplasia (BPH)."7.70Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. ( Borkowski, A; Chon, JK; Isaacs, JT; Jacobs, SC; Kyprianou, N; Partin, AW, 1999)
"We identified 69 men with symptomatic benign prostatic hyperplasia (BPH) who had been receiving 5 mg/day (n = 33) of finasteride or 2 to 5 mg/day (n = 14) of terazosin or no therapy ("watchful waiting") (n = 22)."7.69Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. ( Andriole, GL; Catalona, WJ; Keetch, DW; Ratliff, TL, 1997)
"The once-daily alpha 1 blocker terazosin was administered to 36 men with symptomatic benign prostatic hyperplasia (BPH) who had previously been scheduled for transurethral resection of the prostate (TURP)."7.68The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin. ( Woods, AL, 1992)
"The effects of prazosin HCl on the urethral pressure profile (UPP) were studied in 14 patients with benign prostatic hyperplasia."7.68Effects of prazosin HCl on the urethral pressure profile in patients with benign prostatic hyperplasia. ( Ishibe, T; Kawashita, E; Nakamura, K; Osumi, Y; Usui, T, 1990)
"The efficacy and safety of terazosin was evaluated in 28 normotensive patients with symptomatic benign prostatic hyperplasia (BPH) ranging in age between 52-72 years."7.67The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Wozniak-Petrofsky, J, 1989)
"The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50."6.73Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. ( Li, HZ; Wang, W; Xiao, H; Yang, Y; Zhang, X; Zhang, Y; Zhao, XF, 2007)
"Tamsulosin (0."6.69A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. ( Hirao, Y; Kamidono, S; Kishimoto, T; Kurita, T; Okada, H; Okajima, E; Okuyama, A; Ozono, S; Park, Y; Yamamoto, K; Yoshioka, T, 2000)
"Treatment with terazosin was initiated with 1 mg daily for 3 days, followed by 2 mg daily for 25 days."6.68The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. ( Auerbach, S; Kaplan, SA; Lloyd, LK; Milam, DE; Oesterling, JE; Padley, RJ; Roehrborn, CG, 1996)
"All terazosin treatment groups exhibited significantly greater decreases in total Boyarsky symptom score than the placebo group."6.67A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. ( Auerbach, S; Leifer, G; Lepor, H; Lowe, F; Madsen, P; Moon, T; Narayan, P; Puras-Baez, A; Soloway, M, 1992)
"All terazosin treatment groups showed dramatic improvement in obstructive symptoms when compared with the placebo group, but these differences were not statistically significant because of the small numbers of patients in each group."6.67Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. ( Buckley, JF; Chilton, CP; Ibrahim, I; Kaisary, AV; Kirk, D; Lloyd, SN, 1992)
"Terazosin was shown to have a four hundred-fold greater affinity for alpha-1 binding sites."6.66Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. ( Baumann, M; Gup, DI; Lepor, H; Shapiro, E, 1988)
"Terazosin is an alpha 1 receptor antagonist which has been shown in placebo-controlled trials to significantly improve American Urology Association (AUA) symptom and quality-of-life scores and symptom problem index ('bother' score), as well as increase peak urinary flow rate, in men with BPH."6.40Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia. ( Goa, KL; Plosker, GL, 1997)
"The present study aims to assess and compare the effects of carvedilol and terazosin plus enalapril on lower urinary tract symptoms (LUTS), the urine flow, and blood pressure (BP) in patients with moderate hypertension (HTN) and benign prostatic hyperplasia (BPH)."5.41A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. ( DalirAkbari, N; Farshi, A; Khalili, M; Mahmoudinezhad, M; Zomorrodi, A, 2021)
"In terazosin treated patients, improvement after 3 months were as follows, IPSS 3."5.33Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. ( Anwarul Islam, AK; Kashem, MA; Kibria, SA; Shameem, IA, 2005)
"Medical treatment of benign prostatic hyperplasia (BPH) targets relief of symptoms by causing either relaxation of the prostatic smooth muscle with alpha1 adrenergic blockade, or shrinkage of the gland with 5alpha-reductase inhibitors."5.31Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. ( Borkowski, A; Chon, JK; Glassman, DT; Jacobs, SC; Kyprianou, N, 2001)
"Terazosin treatment, even 2 mg."5.31Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. ( Furuya, S; Itoh, N; Masumori, N; Ogura, H; Sato, Y; Takahashi, A; Tanaka, Y; Tsukamoto, T, 2002)
"Prazosin HCl was administered in dosages of 1."5.28Clinical studies on the effectiveness of prazosin HCl (Minipress tablets) in the treatment of dysuria accompanying benign prostatic hyperplasia. ( Aoki, H; Kobayashi, M; Numazato, S; Ohhori, M; Ohninata, M; Sakuma, S; Shiraiwa, Y; Tsuzuki, T; Yamaguchi, O; Yokota, T, 1990)
" One hundred patients with Benign Prostatic Hyperplasia were randomly divided into 2 equal groups receiving prostafit and prazosin, respectively."5.19Pumpkin seed oil (prostafit) or prazosin? Which one is better in the treatment of symptomatic benign prostatic hyperplasia. ( Mahboob, MR; Masuminia, M; Mohammadi, S; Shirvan, MK, 2014)
"This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension."5.14[Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. ( Fang, J; Li, YL; Liu, HP; Qin, XH; Xu, XP; Yang, C; Zhang, X, 2009)
"Terazosin is an alpha1-selective adrenoceptor blocking agent that has been reported in many clinical trials to be an effective choice for the treatment of benign prostatic hyperplasia (BPH)."5.12Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. ( Lan, SK; Ou, JH; Tsai, YS; Tzai, TS, 2007)
"Finasteride, which inhibits the enzyme 5 alpha-reductase, reduces prostate size and relieves the symptoms of benign prostatic hyperplasia (BPH) in men with enlarged prostates."5.11Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. ( Doggrell, SA, 2004)
"The objective of the present study was to evaluate the efficacy and safety of Prostina, a multi-ingredient herbal formulation in benign prostatic hyperplasia (BPH) in comparison with terazosin."5.11Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia. ( Biswas, NR; Dogra, PN; Kumar, V; Mani, K; Ravi, AK, 2005)
"To clarify the influence of hypertension on lower urinary tract symptoms (LUTS) we examined the relationship between blood pressure, LUTS, and the effect of terazosin on LUTS in patients with benign prostatic hyperplasia (BPH)."5.10Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. ( Gakiya, M; Goya, M; Hatano, T; Ikehara, A; Kadekawa, K; Nakayama, T; Nashiro, F; Ogawa, Y; Sugaya, K, 2003)
"To review and assess the cardiovascular safety of the alpha1-blocker terazosin when used to treat symptomatic benign prostatic hyperplasia (BPH) in patients taking concurrent antihypertensive medications."5.09Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. ( Lowe, FC; Olson, PJ; Padley, RJ, 1999)
" This result was not significant but suggested a favorable effect of terazosin on diminishing the risk of coronary heart disease."5.09[Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy]. ( Kageyama, S; Tamaki, M; Ueda, T, 1999)
"The objective of this open randomized clinical study was to compare the short-term efficacy and safety of three alpha-1 blockers, prazosin, terazosin and tamsulosin, in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)."5.09Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. ( Tsujii, T, 2000)
"To evaluate the efficacy and to describe the modalities of use of terazosin hydrochloride dihydrate, prescribed under conditions of routine clinical practice to a vast population of patients with benign prostatic hyperplasia (BPH)."5.09[Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination]. ( Boumendil, O; Reitz, C; Rossi, D; Serment, G, 2000)
"In a randomized, controlled clinical trial, 52 patients with lower urinary tract symptoms due to benign prostatic hyperplasia received terazosin treatment and 51 underwent microwave treatment under topical anesthesia."5.09Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. ( Basharkhah, A; Djavan, B; Fakhari, M; Harik, M; Marberger, M; Planz, B; Remzi, M; Roehrborn, CG; Seitz, C; Waldert, M, 2001)
"We compared the efficacy of once a day administration of terazosin hydrochloride with that of twice a day administration for benign prostatic hyperplasia (BPH) patients."5.09[A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin]. ( Ikemoto, I; Ohishi, Y; Ohnishi, T; Suzuki, H; Suzuki, Y; Yamazaki, H, 2001)
"To evaluate long-term efficacy and safety of terazosin, a selective alpha 1 blocker, in the treatment of benign prostatic hyperplasia (BPH)."5.08Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. ( Lepor, H, 1995)
"We developed a decision analytic model to compare the costs of treatment for an initial 2-year period with finasteride, terazosin, and transurethral resection of the prostate (TURP) in men with at least moderate symptoms of benign prostatic hyperplasia (BPH)."5.08Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. ( Chmiel, JJ; Hillman, AL; Lowe, FC; McDaniel, RL, 1995)
"This is a controlled efficacy study with doxazosin (4 mg/day) in the long-term management of 64 ambulatory patients with benign prostatic hyperplasia (BPH)."5.08Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One). ( Dutkiewicz, S; Witeska, A, 1995)
"To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha(1)-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH)."5.08The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. ( Deverka, PA; Hillman, AL; Mason, MF; Maurath, CJ; Oesterling, JE; Padley, RJ; Peskin, E; Roehrborn, CG; Schwartz, JS; Willian, MK, 1996)
"We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH)."5.08Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. ( de La Rosette, JJ; de Wildt, MJ; Debruyne, FM; Rosier, FW; van Iersel, MP; Witjes, WP, 1996)
"This study was designed to evaluate the safety and efficacy of the selective alpha 1-adrenoceptor blocker terazosin in the treatment of benign prostatic hyperplasia (BPH)."5.08A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. ( Barkin, J; Beland, G; Boake, RC; Casey, RW; Elhilali, MM; Fradet, Y; Klotz, LH; Orovan, WL; Ramsey, EW; Schick, E; Trachtenberg, J, 1996)
"We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia."5.08The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. ( Barry, MJ; Brawer, MK; Dixon, CM; Gormley, G; Haakenson, C; Lepor, H; Machi, M; Narayan, P; Padley, RJ; Williford, WO, 1996)
"To evaluate the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia (BPH)."5.08The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. ( Debruyne, FM; Fitzpatrick, J; Kirby, R; Kirk, D; Prezioso, D; Witjes, WP, 1996)
"2 mg) of tamsulosin, a selective alpha 1A-adrenoreceptor antagonist, with an increasing dose (1-5 mg) of terazosin, a non-selective antagonist, in the treatment of urinary outflow obstruction associated with benign prostatic hyperplasia (BPH) in Korean patients."5.08Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. ( Lee, C; Lee, E, 1997)
"A total of 1,229 subjects with clinical benign prostatic hyperplasia (BPH) were randomized to 1 year of placebo, finasteride, terazosin or drug combination."5.08The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. ( Barry, MJ; Haakenson, C; Jones, K; Lepor, H; Williford, WO, 1998)
"To determine the effects of terazosin on blood pressure and on antihypertensive therapy when used in managing benign prostatic hyperplasia (BPH)."5.08Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. ( Kirby, RS, 1998)
"To examine the clinical usefulness of selective and non-selective alpha 1-adrenoceptor antagonists, we compared a selective (tamsulosin) and non-selective (terazosin) alpha 1-adrenoceptor antagonists in the treatment of Chinese patients with benign prostatic hyperplasia (BPH)."5.08Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. ( Gu, FL; Guo, YL; Na, YJ, 1998)
"Alfuzosin, a selective alpha 1-adrenoceptor antagonist which is effective in the symptomatic treatment of benign prostatic hyperplasia (BPH), was compared with prazosin, another drug commonly used for the same purpose."5.07Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. ( Blondin, P; Buzelin, JM; Hebert, M, 1993)
"To evaluate the efficacy and tolerability of terazosin, a long-acting selective alpha 1-receptor antagonist, in patients with benign prostatic hyperplasia."5.07Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. ( Adams, G; Brawer, MK; Epstein, H, 1993)
"The purpose of this trial was to study the use of terazosin in nonbacterial prostatitis/prostatodynia, and to evaluate a new symptom score sheet for this disease."5.07Use of terazosin in prostatodynia and validation of a symptom score questionnaire. ( Moon, TD; Neal, DE, 1994)
"This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)."5.07Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. ( Lowe, FC, 1994)
"Terazosin is safe and effective in treating concomitant hypertension and BPH."5.07Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial. ( Guthrie, R, 1994)
"This randomised, placebo-controlled, double-blind study was performed to evaluate the efficacy and safety of once-a-day terazosin (10 mg/d) in ambulatory patients (n = 57) with benign prostatic hyperplasia (BPH)."5.07Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. ( Fabricius, PG; Hannaford, JM, 1992)
"The purpose of this multicentre, randomised, placebo-controlled, double-blind study was to verify the safety and efficacy of terazosin, an alpha 1 adrenergic blocker, in patients with benign prostatic hyperplasia (BPH)."5.07Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. ( Di Silverio, F, 1992)
"The primary objective of the present interim analysis of an open label study initiated in December 1988 is to provide further insight into the long-term safety, efficacy and compliance of terazosin, a long-acting selective alpha 1-blocker, for the treatment of symptomatic benign prostatic hyperplasia (BPH)."5.07The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Meretyk, S, 1992)
"Terazosin, a selective, long-acting alpha 1-adrenergic blocker, was evaluated in 44 men with benign prostatic hyperplasia."5.07Efficacy of terazosin in patients with benign prostatic hyperplasia. ( Laddu, A; Matzkin, H; Rangel, MC; Soloway, MS, 1992)
"A series of 93 normotensive patients with benign prostatic hyperplasia and maximum urinary flow rates < 15 ml/s, treated at 2 hospital centres using an identical protocol, was randomly assigned to receive a 12-week course of treatment with prazosin or placebo in a double-blind parallel group trial."5.07A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. ( Abrams, PH; Chapple, CR; Christmas, TJ; Milroy, EJ; Stott, M, 1992)
"This randomized, placebo-controlled, double-blind study was performed to evaluate the efficacy and safety of once-a-day terazosin (10 mg/day) in ambulatory patients (n = 57) with benign prostatic hyperplasia (BPH)."5.06Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. ( Dunzendorfer, U; Fabricius, PG; Hannaford, JM; Maurath, C; Weizert, P, 1990)
"Prazosin is well known to most physicians as an effective antihypertensive medication, but its therapeutic value in many cases of benign prostatic hyperplasia (BPH) may be unfamiliar to many."5.06Clinical overview of prazosin in the treatment of prostatic obstruction. ( Milroy, E, 1990)
"Prazosin, a selective alpha 1-adrenoceptor blocker, was compared with Paraprost in a double-blind, multi-institutional study in patients with benign prostatic hyperplasia."5.06Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. ( Aoki, H; Kobayashi, M; Ohinata, M; Ohori, M; Shiraiwa, Y; Tsuzuki, T; Yamaguchi, O; Yokota, T, 1990)
"Fifty-eight normotensive patients with benign prostatic hyperplasia and maximum urinary flow rates of less than 15 ml/s were randomly assigned to receive a 12-week course of treatment with prazosin or placebo in a double-blind parallel group trial."5.06A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction. ( Chapple, CR; Christmas, TJ; Milroy, EJ, 1990)
"The efficacy and safety of terazosin, a selective long-acting alpha-1-adrenergic blocker, were evaluated in 45 normotensive patients with symptomatic benign prostatic hyperplasia ranging from 50 to 76 years old."5.06A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Sunshine, H, 1990)
"In a double blind cross-over study, the selective alpha 1-adrenoceptor blocker prazosin was given to eleven men with a non-hyperplastic prostate and with symptoms of bladder neck obstruction."5.06Effects of prazosin in men with symptoms of bladder neck obstruction and a non-hyperplastic prostate. ( Andersson, KE; Hedlund, H, 1989)
"The effectiveness and safety of tamsulosin and terazosin for patients with benign prostatic hyperplasia (BPH) was evaluated by literature review."4.85Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. ( Chen, W; Dong, Z; Gao, W; Liu, Y; Wang, Z; Yang, K, 2009)
"To determine the effectiveness of the long-acting alpha(1)-adrenergic receptor blocking agent terazosin compared with placebo on lower urinary tract symptoms and peak urinary flow rate in men with clinical benign prostatic hyperplasia."4.81Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. ( Boyle, P; Manski, R; Padley, RJ; Robertson, C; Roehrborn, CG, 2001)
"Naftopidil, a phenylpiperazine derivative, is a novel alpha 1-adrenoceptor antagonist and is new drug for the bladder outlet obstruction in patients with benign prostatic hyperplasia (BPH)."4.80[Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia]. ( Ikegaki, I, 2000)
"In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia."4.79Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. ( Lowe, FC; McKiernan, JM, 1997)
"Terazosin is a selective alpha 1 adrenoceptor antagonist that is currently under clinical investigation for the treatment of clinical BPH."3.77Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. ( Laddu, A; Lepor, H, 1992)
" The present review of terazosin in males with symptomatic BPH supports the following conclusions: (1) the dose of terazosin can be safely titrated to 10 mg in normotensive and hypertensive patients with symptomatic BPH; (2) the adverse events associated with doses of terazosin up to 10 mg are relatively mild and reversible; and (3) the improvements in the outcome parameters (symptom scores and urinary flow rates) are clinically and statistically significant."3.77The efficacy and safety of terazosin for the treatment of symptomatic BPH. ( Henry, D; Laddu, AR; Lepor, H, 1991)
" The validity and reliability were assessed in 76 patients with urinary symptoms due to benign prostatic hyperplasia (BPH) and in 63 control subjects without BPH; 25 patients had transurethral resection of prostate (TURP) whereas the remaining 51 patients were treated with terazosin."3.76Development and validation of an Arabic version of the International Prostate Symptom Score. ( Hammad, FT; Kaya, MA, 2010)
"Although benign prostatic hypertrophy is the most common cause of urinary tract symptoms in men, the cause is still unclear."3.76Alpha-adrenoceptor inhibitors in the treatment of benign prostatic hyperplasia. ( Kirby, RS, 1989)
"To investigate the effects of amlodipine, a dihydropyridine calcium-channel blocker, alone or combined with terazosin, on urodynamics in rats with benign prostatic hyperplasia (BPH) and in female rats with detrusor instability (DI)."3.75Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity. ( Chen, GL; Liu, HP; Liu, P; Xu, XP, 2009)
"The objective of this meta-analysis of randomized controlled trials (RCTs) of terazosin versus placebo in men with benign prostatic hyperplasia (BPH) was to evaluate the effect of terazosin on lower urinary tract symptoms."3.72Effect of terazosin on clinical benign prostatic hyperplasia in older adults. ( Ahmed, A; Mudiyala, R, 2003)
"Thirty-six male patients with symptomatic benign prostatic hyperplasia (BPH) with a serum prostate-specific antigen level of 4-10 ng/mL underwent MRI with body coil, transrectal prostate ultrasonography and biopsy prior to terazosin therapy."3.71Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia. ( Alkibay, T; Ataoglu , O; Atilla, S; Isen, K; Isik, S; Sezer, C; Sinik, Z; Sözen, S, 2001)
"We evaluated the short-term efficacy of terazosin for treating symptomatic benign prostatic hyperplasia (BPH)."3.71The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia. ( Akimoto, M; Horiuchi, K; Suzuki, Y; Tsuboi, N; Yoshida, K, 2001)
"Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation."3.71Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001)
"A total of 34 men with benign prostatic hyperplasia (BPH) who have been on terazosin treatment (for the obstructive symptoms) were pathologically diagnosed with prostate cancer following surgery."3.71Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. ( Borkowski, A; Isaacs, JT; Jacobs, SC; Keledjian, K; Kim, G; Kyprianou, N, 2001)
"To determine the changes in plasma lipid levels in symptomatic benign prostatic hyperplasia (BPH) patients receiving terazosin treatment."3.71Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia. ( Akbay, E; Bozlu, M; Cayan, S; Doruk, E; Ulusoy, E, 2001)
"New types of alpha1-adrenoceptor antagonists (tamsulosin, KMD-3213 and JTH-601) are currently receiving a great deal of attention, especially in terms of developing effective therapeutic agents to treat bladder outlet obstruction with less side effects, such as postural hypotension, in patients with benign prostatic hyperplasia (BPH)."3.70In vivo receptor binding of novel alpha1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia. ( Kawabe, K; Kimura, R; Ohkura, T; Yamada, S, 1998)
"Recent evidence indicated that an alpha 1 blocker, doxazosin, induces prostate apoptosis in patients with benign prostatic hyperplasia (BPH)."3.70Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. ( Borkowski, A; Chon, JK; Isaacs, JT; Jacobs, SC; Kyprianou, N; Partin, AW, 1999)
"To evaluate the use and problems of alpha-receptor blockade with prazosin among patients in Nigeria with benign prostatic hyperplasia (BPH) who face a prolonged wait for a prostatectomy."3.69alpha-receptor blockade for benign prostatic hyperplasia: uses and problems in a developing country. ( Ogbonna, BC; Okeahialam, BN; Ramyil, VM, 1997)
"We identified 69 men with symptomatic benign prostatic hyperplasia (BPH) who had been receiving 5 mg/day (n = 33) of finasteride or 2 to 5 mg/day (n = 14) of terazosin or no therapy ("watchful waiting") (n = 22)."3.69Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. ( Andriole, GL; Catalona, WJ; Keetch, DW; Ratliff, TL, 1997)
"To determine the safety and efficacy of alpha blockade with doxazosin and terazosin in men over the age of 80 years with symptomatic benign prostatic hyperplasia (BPH)."3.69The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years. ( Ikeguchi, E; Kaplan, SA; Santarosa, RP; Te, AE, 1997)
"The adrenergic alpha-1 and -2 adrenoceptors in six human hypertrophied prostatic adenomas were measured in the saturation experiment using 3H-prazosin and 3H-yohimbine."3.68[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas]. ( Kondo, S; Morita, T, 1992)
"The once-daily alpha 1 blocker terazosin was administered to 36 men with symptomatic benign prostatic hyperplasia (BPH) who had previously been scheduled for transurethral resection of the prostate (TURP)."3.68The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin. ( Woods, AL, 1992)
"The effects of prazosin HCl on the urethral pressure profile (UPP) were studied in 14 patients with benign prostatic hyperplasia."3.68Effects of prazosin HCl on the urethral pressure profile in patients with benign prostatic hyperplasia. ( Ishibe, T; Kawashita, E; Nakamura, K; Osumi, Y; Usui, T, 1990)
"The adrenergic alpha-1 and -2 adrenoceptors in human hypertrophied and non-hypertrophied prostatic adenomas were measured in the saturation experiment using 3H-prazosin and 3H-yohimbine."3.68[Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity]. ( Morita, T, 1991)
"Bladder outlet obstruction in men with benign prostatic hyperplasia is decreased following administration of prazosin, a selective alpha1 adrenergic antagonist."3.67Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. ( Lepor, H; Shapiro, E, 1984)
"Clinical trials are currently underway to evaluate the efficacy of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)."3.67The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain. ( Baumann, M; Lepor, H; Shapiro, E, 1988)
"The effect of prazosin on epinephrine-induced contractions of human benign prostatic hyperplasia strips was studied."3.67[Effect of prazosin on human prostatic adenoma tissue]. ( Kaminka, ME; Mashkovskiĭ, MD; Pytel', IuA; Vinarov, AZ; Zhirnikova, ML, 1988)
"The efficacy and safety of terazosin was evaluated in 28 normotensive patients with symptomatic benign prostatic hyperplasia (BPH) ranging in age between 52-72 years."3.67The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Wozniak-Petrofsky, J, 1989)
"The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50."2.73Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. ( Li, HZ; Wang, W; Xiao, H; Yang, Y; Zhang, X; Zhang, Y; Zhao, XF, 2007)
" No unknown adverse reactions were observed in either groups, and the drugs were shown to be highly safe."2.70[The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy]. ( Fujioka, T; Goto, Y; Isurugi, K; Katoh, T; Numasato, S; Obara, W; Omori, S; Suzuki, Y, 2001)
"Once-daily dosing of TAM after breakfast at a fixed dose level (0."2.69A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. ( de Mey, C; McEwen, J; Michel, MC; Moreland, T, 1998)
"Medical management of benign prostatic hyperplasia (BPH) giving rise to lower urinary tract symptomatology (LUTS) has emerged as the mainstay for first-line therapy."2.69Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. ( Brawer, MK; Jones, K; Lepor, H; Lin, DW; Williford, WO, 1999)
"We determined the mechanism of adverse events associated with alpha1-blockers for treating benign prostatic hyperplasia (BPH)."2.69The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. ( Jones, K; Lepor, H; Williford, W, 2000)
"Tamsulosin (0."2.69A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. ( Hirao, Y; Kamidono, S; Kishimoto, T; Kurita, T; Okada, H; Okajima, E; Okuyama, A; Ozono, S; Park, Y; Yamamoto, K; Yoshioka, T, 2000)
" Parameters evaluated included Boyarsky symptom score (Sx), peak uroflow (Qmax), blood pressure and occurrence of adverse events."2.68Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. ( Kaplan, SA; Olsson, CA; Soldo, KA, 1995)
"Treatment with terazosin was initiated with 1 mg daily for 3 days, followed by 2 mg daily for 25 days."2.68The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. ( Auerbach, S; Kaplan, SA; Lloyd, LK; Milam, DE; Oesterling, JE; Padley, RJ; Roehrborn, CG, 1996)
"Terazosin treatment resulted in significant changes in flow rate and residual urine, however, changes in flow rates were not influenced by prostate size, while a marked decrease in residual urine was found in patients with large prostates."2.68Influence of prostate size on terazosin efficacy. ( Becopoulos, T; Christofis, I; Mitropoulos, D, 1997)
"Alternative treatments for benign prostatic hyperplasia (BPH) are the source of much discussion at present."2.67Comparative study of selective alpha 1-adrenoceptor blockade versus surgery in the treatment of prostatic obstruction. ( Chapple, CR; Milroy, EJ; Noble, JG, 1993)
"All terazosin treatment groups exhibited significantly greater decreases in total Boyarsky symptom score than the placebo group."2.67A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. ( Auerbach, S; Leifer, G; Lepor, H; Lowe, F; Madsen, P; Moon, T; Narayan, P; Puras-Baez, A; Soloway, M, 1992)
"All terazosin treatment groups showed dramatic improvement in obstructive symptoms when compared with the placebo group, but these differences were not statistically significant because of the small numbers of patients in each group."2.67Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. ( Buckley, JF; Chilton, CP; Ibrahim, I; Kaisary, AV; Kirk, D; Lloyd, SN, 1992)
"Oral carbachol has no effects on bladder emptying in these patients."2.66Effects of prazosin and carbachol in patients with benign prostatic obstruction. ( Andersson, KE; Hedlund, H, 1988)
"Terazosin is an alpha-1 adrenergic blocking agent currently marketed as an antihypertensive."2.66Clinical experience: symptomatic management of BPH with terazosin. ( Dunzendorfer, U, 1988)
"Terazosin was shown to have a four hundred-fold greater affinity for alpha-1 binding sites."2.66Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. ( Baumann, M; Gup, DI; Lepor, H; Shapiro, E, 1988)
"Medical treatment for benign prostatic hyperplasia is reviewed by the author."2.42[Pharmacologic treatment of benign prostatic hyperplasia]. ( Romics, I, 2003)
"All published data on benign prostatic hyperplasia in Saudi Arabia was reviewed."2.41Benign prostatic hyperplasia. The Saudi perspective in the year 2000. ( Atwa, MA; Mahassini, SH; Mosli, HA, 2000)
"Men with moderate symptoms of benign prostatic hyperplasia (BPH) are the best candidates for medical treatment, while surgery is usually indicated for patients with severe symptoms."2.40Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. ( Eri, LM; Tveter, KJ, 1997)
"Terazosin is an alpha 1 receptor antagonist which has been shown in placebo-controlled trials to significantly improve American Urology Association (AUA) symptom and quality-of-life scores and symptom problem index ('bother' score), as well as increase peak urinary flow rate, in men with BPH."2.40Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia. ( Goa, KL; Plosker, GL, 1997)
"dizziness and orthostatic hypotension)."2.40A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. ( Djavan, B; Marberger, M, 1999)
"Symptomatic benign prostatic hyperplasia (BPH) is a common condition in older men and has a significant impact on their daily lives."2.39Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. ( Chapple, CR, 1996)
"Prazosin treatment of HUVECs resulted in reduced MCL-1 expression, increased Bad, and Bcl-xL expression, cytochrome c release, and induction of apoptosis via the intrinsic apoptosis pathway."1.37Anti-angiogenic effects and mechanism of prazosin. ( Chueh, SC; Guh, JH; Liao, CH; Yu, HJ, 2011)
"Since trial results for benign prostatic hyperplasia phytotherapeutic agents are inconsistent, they may also be contaminated."1.36Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. ( Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA, 2010)
"Forty males with benign prostatic hyperplasia (BPH) applying to the Department of Urology with lower urinary tract symptoms (LUTS) were enrolled in the study consecutively."1.35Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals. ( Adayener, C; Akyol, I; Ates, F; Iseri, C; Senkul, T; Yilmaz, O, 2008)
"Treatment with terazosin can reduce patients' episodes of nocturia both subjectively and objectively in some men with LUTS."1.33alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction. ( Kim, SW; Ku, JH; Paick, JS; Shin, JW; Yang, JH, 2006)
"Hormone treatment induced benign prostatic hyperplasia and resulted in detrusor overactivity, as determined by cystometry."1.33A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. ( Akiyama, K; Kobayashi, M; Tatemichi, S; Uruno, T; Yamazaki, Y; Yokoyama, O, 2006)
"In terazosin treated patients, improvement after 3 months were as follows, IPSS 3."1.33Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. ( Anwarul Islam, AK; Kashem, MA; Kibria, SA; Shameem, IA, 2005)
"Men participating in the 2001 and 2002 Prostate Cancer Awareness Week screening for prostate cancer were given a self-administered questionnaire."1.32Herbal and vitamin supplement use in a prostate cancer screening population. ( Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C, 2004)
"Benign prostate hyperplasia (BPH) and prostate cancer established that disruption of the molecular mechanisms that regulate apoptosis and cell proliferation among the stromal and epithelial cell populations, may underlie the neoplastic development that characterizes the aging gland."1.31Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. ( Benning, CM; Chon, J; Kyprianou, N, 2000)
"Medical treatment of benign prostatic hyperplasia (BPH) targets relief of symptoms by causing either relaxation of the prostatic smooth muscle with alpha1 adrenergic blockade, or shrinkage of the gland with 5alpha-reductase inhibitors."1.31Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. ( Borkowski, A; Chon, JK; Glassman, DT; Jacobs, SC; Kyprianou, N, 2001)
"Tamsulosin has a markedly lower re-treatment percentage than alfuzosin and terazosin."1.31Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. ( de la Rosette, JJ; Floratos, DL; Kiemeney, LA; Kortmann, BB; Rossi, C; Sonke, GS, 2002)
"Terazosin treatment, even 2 mg."1.31Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. ( Furuya, S; Itoh, N; Masumori, N; Ogura, H; Sato, Y; Takahashi, A; Tanaka, Y; Tsukamoto, T, 2002)
"In patients without bladder outlet obstruction (BOO), improvement in maximum flow and symptom scores with little change in the degree of obstruction was most apparent, whereas a decrease of detrusor pressure at maximum flow was observed mainly in patients with BOO."1.30Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. ( de la Rosette, JJ; Debruyne, FM; Neal, DE; Robertson, A; Rosier, PF; Witjes, WP, 1997)
"The purpose of this study was to determine the potency and selectivity of the alpha-1 adrenergic receptor antagonist terazosin based on relationships between plasma concentrations and blockade of intraurethral pressure (IUP) and mean arterial pressure (MAP) responses after single dosing and to determine cumulative effects after repeated dosing."1.30Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin. ( Brune, ME; Hancock, AA; Katwala, SP; Kerwin, JF; Milicic, I; Witte, DG, 1997)
"In 21 prostatic adenomas, NE were identified by specific antisera against neuroendocrine markers (chromogranin-A, synaptophysin), histamine, and histidine decarboxylase (HDC); a rate HDC-cDNA probe was used to detect this enzyme by in situ hybridization."1.30Neurohormonal stimulation of histamine release from neuroendocrine cells of the human adenomatous prostate. ( Bali, JP; Bancel, E; Boyer, JC; Choquet, A; Combettes, S; Costa, P; Gaspard, C; Guitton, C; Mottet, N; Polge, A, 1998)
" Dosage was started at 1 mg/d and increased as tolerated to 2, 5, and 10 mg/d over the test period."1.29Effect of terazosin on urine storage and voiding in the aging male with prostatism. ( Bottaccini, MR; Gleason, DM, 1994)
"Benign prostatic hypertrophy provokes clinical manifestations correlated on one hand to a static obstructive component, due to the increase in glandular size, and on the other hand to a dynamic component, controlled by the alpha adrenergic autonomic system which gives the smooth muscular tonus of the prostatic adenoma."1.29[Terazosin in the treatment of benign prostatic hypertrophy]. ( Andres, M; Carmignani, L; De Cobelli, O; Kocjancic, E; Musci, R; Panizzutti, M; Rocco, F, 1995)
"Medical management of benign prostatic hyperplasia (BPH) is an alternative to surgical treatment of this disease."1.29Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. ( Breslin, D; Chou, TC; Felsen, D; Fields, DW; Kane, M; Marion, DN; Vaughan, ED, 1993)
" The daily dosage of terazosin was titrated to 5 mg over a 2-week interval."1.28The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. ( Lepor, H; Machi, G, 1992)
"Prazosin HCl was administered in dosages of 1."1.28Clinical studies on the effectiveness of prazosin HCl (Minipress tablets) in the treatment of dysuria accompanying benign prostatic hyperplasia. ( Aoki, H; Kobayashi, M; Numazato, S; Ohhori, M; Ohninata, M; Sakuma, S; Shiraiwa, Y; Tsuzuki, T; Yamaguchi, O; Yokota, T, 1990)
"Prazosin HCl was administered to 20 patients with urinary obstructions associated with prostatic hypertrophy."1.28The efficacy of prazosin HCl in the treatment of urinary flow obstruction due to prostatic hypertrophy. ( Gotoh, M; Ito, K; Kobayashi, M; Kondo, A; Otani, T; Saito, M; Takita, T, 1990)
" The comparison of clinical results and serum plasma levels enabled optimalization of the dosage in long-term therapy."1.28Prazosin concentration monitoring in the treatment of prostatic adenoma. ( Dutkiewicz, S; Filipek, M, 1991)

Research

Studies (268)

TimeframeStudies, this research(%)All Research%
pre-199024 (8.96)18.7374
1990's145 (54.10)18.2507
2000's79 (29.48)29.6817
2010's19 (7.09)24.3611
2020's1 (0.37)2.80

Authors

AuthorsStudies
Kenny, B1
Ballard, S1
Blagg, J1
Fox, D1
Elworthy, TR1
Ford, AP1
Bantle, GW1
Morgans, DJ1
Ozer, RS1
Palmer, WS1
Repke, DB1
Romero, M1
Sandoval, L1
Sjogren, EB1
Talamás, FX1
Vazquez, A1
Wu, H1
Arredondo, NF1
Blue, DR1
DeSousa, A1
Gross, LM1
Kava, MS1
Lesnick, JD1
Vimont, RL1
Williams, TJ1
Zhu, QM1
Pfister, JR1
Clarke, DE2
Nagarathnam, D2
Wetzel, JM2
Miao, SW2
Marzabadi, MR2
Chiu, G2
Wong, WC2
Hong, X2
Fang, J3
Forray, C2
Branchek, TA1
Heydorn, WE1
Chang, RS2
Broten, T1
Schorn, TW1
Gluchowski, C2
Chen, TB1
O'Malley, SS1
Li, MY1
Fang, H1
Xia, L1
Ohyama, K1
Hori, Y1
Sugiura, M1
Farshi, A1
DalirAkbari, N1
Zomorrodi, A1
Khalili, M1
Mahmoudinezhad, M1
Nadeem, HMR1
Mohiuddin, E1
UdDin, S1
Daniyal, M1
Usmanghani, K1
Sun, JM1
Liu, P2
Han, WJ1
Araki, T1
Monden, K1
Araki, M1
Shirvan, MK1
Mahboob, MR1
Masuminia, M1
Mohammadi, S1
Cyrus, A1
Kabir, A1
Goodarzi, D1
Talaei, A1
Moradi, A1
Rafiee, M1
Moghimi, M1
Shahbazi, E1
Farmani, E1
Sosnovskiĭ, SO1
Kheĭfets, VKh1
Kagan, OF1
Barkin, J2
Diles, D1
Franks, B1
Berner, T1
Zhang, Y2
Shamie, N1
Daneshmand, S1
Belayneh, M1
Korownyk, C1
Mamalis, N1
Paick, JS3
Cho, MC1
Song, SH1
Kim, SW2
Ku, JH4
Bar-Yosef, Y1
Mabjeesh, NJ1
Laufer, M1
Neulander, EZ1
Kaver, I1
Matzkin, H2
Yang, T1
Zhang, XQ1
Feng, YW1
Vaughan, CP1
Endeshaw, Y1
Nagamia, Z1
Ouslander, JG1
Johnson, TM2
Prata, TS1
Palmiero, PM1
Angelilli, A1
Sbeity, Z1
De Moraes, CG1
Liebmann, JM1
Ritch, R1
Liu, HP2
Chen, GL1
Xu, XP2
Yang, C1
Li, YL1
Zhang, X2
Qin, XH1
Hammad, FT1
Kaya, MA1
Dong, Z1
Wang, Z1
Yang, K1
Liu, Y1
Gao, W1
Chen, W1
Li, S1
Lu, A1
Wang, Y1
Elterman, DS1
Lawrentschuk, N1
Guns, E1
Hersey, K1
Adomat, H1
Wood, CA1
Fleshner, N1
Alan, C1
Kırılmaz, B1
Koçoğlu, H1
Ersay, AR1
Ertung, Y1
Eren, AE1
Krome, S1
Liao, CH1
Guh, JH2
Chueh, SC3
Yu, HJ1
Wilt, TJ2
Howe, RW2
Rutks, I1
Macdonald, R2
Desiniotis, A1
Kyprianou, N8
Sherman, JJ1
Welch, RW1
Hill, TM1
McEwen, C1
Abeygunasekera, AM1
de Silva, S1
Gurusingha, A1
Wijeratne, S1
Erdoğru, T1
Ciftcioglu, MA1
Emreoglu, I1
Usta, MF1
Koksal, T1
Ozbilim, G1
Gulkesen, KH1
Baykara, M1
Rutks, IR1
Mudiyala, R1
Ahmed, A1
Yokota, T3
Shishido, K1
Jones, K4
Williford, WO4
Kutner, MH1
Issa, MM1
Lepor, H22
Gonzalez, CM1
McVary, KT1
Romics, I1
Sugaya, K1
Kadekawa, K1
Ikehara, A1
Nakayama, T1
Gakiya, M1
Nashiro, F1
Goya, M1
Hatano, T1
Ogawa, Y1
Barqawi, A1
Gamito, E1
O'Donnell, C1
Crawford, ED2
Tahmatzopoulos, A1
Brown, GA1
Sussman, DO1
Deng, CH1
Chen, HR1
Qiu, SP2
Liu, JZ1
Zheng, KL1
Mei, H1
Doggrell, SA1
Kirby, R2
Samli, MM1
Dincel, C1
Bozlu, M2
Ulusoy, E2
Cayan, S2
Akbay, E4
Görür, S1
Pawar, A1
Fahim, M1
Dogra, PN1
Biswas, NR1
Ravi, AK1
Mani, K1
Kumar, V1
O'Leary, MP1
Shin, JW2
Yang, JH2
Um, JM1
Tatemichi, S1
Akiyama, K2
Kobayashi, M4
Yamazaki, Y1
Yokoyama, O1
Uruno, T1
Anwarul Islam, AK1
Kashem, MA1
Shameem, IA1
Kibria, SA1
Tsai, YS2
Tong, YC1
Cheng, JT1
Lee, CH1
Yang, FS1
Lee, HY1
Yang, Y1
Zhao, XF1
Li, HZ1
Wang, W1
Xiao, H1
Song, YS2
Lan, SK1
Ou, JH1
Tzai, TS1
Yang, MG1
Zhao, XK1
Li, NC1
Wu, SL1
Jin, J1
Kong, CZ1
Ye, ZQ1
Sun, G1
Sun, YH1
Sun, YC1
Wang, XF1
Na, YQ1
Koh, MJ1
Seah, PP1
Tay, YK1
Mancer, K1
Senkul, T1
Yilmaz, O1
Iseri, C1
Adayener, C1
Akyol, I1
Ates, F1
Seak, CJ1
Lin, CC1
Rich, KT1
Safranek, S1
Bouffioux, CR1
Penders, L1
Hedlund, H3
Andersson, KE3
Ek, A1
Kitada, S1
Shapiro, E5
Drescher, P1
Eckert, RE1
Madsen, PO1
Chapple, CR9
Noble, JG1
Milroy, EJ5
Buzelin, JM1
Hebert, M1
Blondin, P1
Konen, JC1
Brawer, MK4
Adams, G1
Epstein, H1
Yu, SM1
Ko, FN2
Chen, J2
Chen, SC1
Chen, CC1
Teng, CM2
Neal, DE2
Moon, TD1
Gleason, DM1
Bottaccini, MR1
Caine, M4
Lowe, FC5
Guthrie, R1
Dutkiewicz, S4
Kałczak, M1
Larosa, M1
Ferretti, S1
Salsi, P1
Simonazzi, M1
Burt, RP1
Andersson, PO1
Greengrass, P1
Wyllie, M1
Marshall, I1
Muramatsu, I1
Oshita, M1
Ohmura, T1
Kigoshi, S1
Akino, H1
Gobara, M1
Okada, K1
Jerant, AF1
Stockamp, K1
Geller, J1
Kirchenbaum, A1
Levine, AC1
Andres, M1
De Cobelli, O1
Carmignani, L1
Musci, R1
Kocjancic, E1
Panizzutti, M1
Rocco, F1
Moon, L1
Pfettscher, S1
Bartek, JK1
McNamee, M1
Kreder, KJ2
Aso, Y2
Homma, Y1
McDaniel, RL1
Chmiel, JJ1
Hillman, AL2
Witeska, A2
Breslin, D1
Fields, DW1
Chou, TC1
Marion, DN1
Kane, M1
Vaughan, ED1
Felsen, D1
Ramsey, EW2
Adriazola Semino, M2
García Cobo, E2
De la Calle Muñoz, I1
Tejeda Bañez, E2
Romero, F1
Steven, ID1
Coffey, GA1
Graham, NM1
Wlodarczyk, J1
Curtis, P1
Kaplan, SA4
Soldo, KA1
Olsson, CA1
Scheen, AJ1
Stepień, K1
Roehrborn, CG7
Oesterling, JE4
Auerbach, S2
Lloyd, LK1
Milam, DE1
Padley, RJ6
Schwartz, JS1
Willian, MK1
Peskin, E1
Mason, MF1
Maurath, CJ1
Deverka, PA1
Witjes, WP4
Rosier, FW1
de Wildt, MJ1
van Iersel, MP1
Debruyne, FM4
de La Rosette, JJ5
Elhilali, MM1
Casey, RW1
Boake, RC1
Beland, G1
Fradet, Y1
Trachtenberg, J1
Orovan, WL1
Schick, E1
Klotz, LH1
Walsh, PC1
Barry, MJ2
Dixon, CM1
Gormley, G1
Haakenson, C2
Machi, M1
Narayan, P2
Constantinou, CE2
Omata, S2
Michel, MC3
Grübbel, B1
Taguchi, K1
Verfürth, F1
Otto, T1
Kröpfl, D1
Lai, MK1
Fitzpatrick, J2
Kirk, D2
Prezioso, D1
Zacks, M1
Kuchel, GA1
DuBeau, CE1
Resnick, NM1
Thien, T1
Lenders, JW1
Bdesha, AS1
Schachter, M1
Sever, P1
Witherow, RO1
Frankel, S1
Brune, ME4
Katwala, SP2
Milicic, I2
Buckner, SA3
Ireland, LM1
Kerwin, JF4
Hancock, AA4
Rosier, PF2
Caris, CT1
Ogbonna, BC1
Okeahialam, BN1
Ramyil, VM1
Haupt, G1
Pannek, J1
Pastor, J1
Schulze, H1
Senge, T1
Eri, LM1
Tveter, KJ1
Nieder, A1
Feser, J1
O'Connell, C1
Dixon, C1
McKiernan, JM1
Sperandeo, M1
Sperandeo, G1
Carella, M1
Bianco, G1
Cera, A1
Scarale, MG1
Viola, M1
Takeda, M1
Hatano, A1
Komeyama, T1
Koizumi, T1
Mizusawa, T1
Kanai, T1
Tomita, Y1
Maruyama, K1
Nagatomo, T1
Evans, MF1
Frank, J1
Robertson, A1
Becopoulos, T1
Mitropoulos, D1
Christofis, I1
Witte, DG1
Moriyama, N3
Murata, S1
Taniguchi, J1
Ishida, N1
Yamazaki, S1
Kawabe, K5
Gómez Sancha, F1
Fernández Arjona, M1
Peinado Ibarra, F1
Fernández Borrell, A1
Mínguez Martínez, R1
Pereira Sanz, I1
Olson, PJ2
Lee, E2
Lee, C1
Meyer, MD2
Altenbach, RJ2
Basha, FZ2
Carroll, WA2
Drizin, I2
Elmore, SW1
Ehrlich, PP1
Lebold, SA2
Tietje, K2
Sippy, KB2
Wendt, MD2
Plata, DJ1
Plagge, F1
Trinkler, FB1
Keetch, DW1
Andriole, GL1
Ratliff, TL1
Catalona, WJ1
Polge, A1
Gaspard, C1
Mottet, N1
Guitton, C1
Boyer, JC1
Choquet, A1
Combettes, S1
Bancel, E1
Costa, P2
Bali, JP1
Te, AE1
Ikeguchi, E1
Santarosa, RP1
Lee, JZ1
Tillig, B1
Perkash, I1
Auger-Pourmarin, L1
Roubert, P1
Chabrier, PE1
Schäfers, RF1
Yamada, S3
Ohkura, T1
Kimura, R2
Suzuki, H2
Beduschi, MC1
Beduschi, R1
de Mey, C1
McEwen, J1
Moreland, T1
Hernández-Cano, N1
Herranz, P1
Lázaro, TE1
Mayor, M1
Casado, M1
Kirby, RS3
Djavan, B3
Shariat, S1
Ghawidel, K1
Marberger, M3
Plosker, GL1
Goa, KL1
Chon, JK2
Borkowski, A3
Partin, AW1
Isaacs, JT2
Jacobs, SC4
Lin, DW1
Albertsen, PC1
Pellissier, JM1
Girman, CJ1
Na, YJ1
Guo, YL1
Gu, FL1
Lee, TH1
Tamaki, M1
Ueda, T1
Kageyama, S1
Jansen, DJ1
Resch, ND1
Hoffman, RM1
Raskind, MA1
Dobie, DJ1
Kanter, ED1
Petrie, EC1
Thompson, CE1
Peskind, ER1
Williford, W1
Cerrato, PL1
Okada, H1
Kamidono, S1
Yoshioka, T1
Okuyama, A1
Ozono, S1
Hirao, Y1
Okajima, E1
Yamamoto, K1
Kishimoto, T1
Park, Y1
Kurita, T2
Tsujii, T2
Fourcade, RO1
Serment, G1
Rossi, D1
Reitz, C1
Boumendil, O1
Clifford, GM1
Farmer, RD2
Ikegaki, I1
Bartsch, G1
Habib, FK1
Ross, M1
Bayne, CW1
Chon, J1
Benning, CM1
Caprino, L1
Blanchard, K1
Hananel, A1
Rutchik, S1
Sullivan, J1
Seitz, C1
Remzi, M1
Fakhari, M1
Waldert, M1
Basharkhah, A1
Planz, B1
Harik, M1
Glassman, DT1
Khokhani, RC1
Suzuki, Y3
Katoh, T1
Isurugi, K1
Obara, W1
Omori, S1
Goto, Y1
Fujioka, T1
Numasato, S1
Isen, K1
Sinik, Z1
Alkibay, T1
Sezer, C1
Sözen, S1
Atilla, S1
Ataoglu , O1
Isik, S1
Ohnishi, T1
Ikemoto, I1
Ohishi, Y1
Yamazaki, H1
Horiuchi, K1
Tsuboi, N1
Yoshida, K1
Akimoto, M1
Souverein, PC1
Herings, RM1
Man in 't Veld, AJ1
Leufkens, HG1
Mosli, HA1
Atwa, MA1
Mahassini, SH1
Bai, H1
Pratt, JK1
Chrischilles, E1
Rubenstein, L1
Chao, J1
Gilden, D1
Shah, H1
Keledjian, K1
Kim, G1
Doruk, E1
Boyle, P1
Robertson, C1
Manski, R1
Akduman, B1
Kortmann, BB1
Rossi, C1
Sonke, GS1
Floratos, DL1
Kiemeney, LA1
Miekos, E1
Trzepizur, Z1
Rózanski, W1
Boniecki, R1
Kusnierz, J1
Jablonowski, Z1
Zydek, C1
Tanaka, Y1
Masumori, N1
Itoh, N1
Sato, Y1
Takahashi, A1
Ogura, H1
Furuya, S1
Tsukamoto, T1
Puras-Baez, A1
Soloway, M1
Lowe, F1
Moon, T1
Leifer, G1
Madsen, P1
Hartanto, V1
Fabricius, PG2
Hannaford, JM2
Lloyd, SN1
Buckley, JF1
Chilton, CP1
Ibrahim, I1
Kaisary, AV1
Laddu, A2
Di Silverio, F1
Azuma, H1
Yamaguchi, T1
Oshima, H1
Heinzl, S1
Machi, G1
Morita, T2
Kondo, S1
Meretyk, S1
Knapp-Maloney, G3
Soloway, MS1
Rangel, MC1
Park, YC1
Nishioka, T1
Arai, Y1
Tomoyoshi, T1
Hayashida, H1
Nagai, N1
Inoue, H1
Kataoka, K1
Kitagawa, Y1
Woods, AL1
Katsumi, T1
Murayama, K1
Lozano Ortega, JL1
Romero Rodríguez, F1
Stott, M1
Abrams, PH1
Christmas, TJ2
Weizert, P1
Dunzendorfer, U3
Maurath, C1
Hamada, K2
Ishima, T1
Milroy, E1
Aoki, H2
Ohninata, M1
Tsuzuki, T2
Ohhori, M1
Shiraiwa, Y2
Yamaguchi, O2
Numazato, S1
Sakuma, S1
Kohama, Y1
Watanabe, H1
Sen, Y1
Yamamoto, Y1
Morioka, M1
Fujita, Y1
Nakamura, K1
Kawashita, E1
Osumi, Y1
Usui, T1
Ishibe, T1
Shimizu, K1
Nakai, K1
Imai, K1
Yamanaka, H1
Kondo, A1
Gotoh, M1
Saito, M1
Takita, T1
Otani, T1
Ito, K1
Ohinata, M1
Ohori, M1
Le Duc, A1
Cariou, G1
Baron, C1
Cukier, J1
Quentel, P1
Faure, G1
Rambeaud, JJ1
Navratil, H1
Richaud, JJ1
Sunshine, H1
Kimura, K1
Murahashi, I1
Ruutu, ML1
Hansson, E1
Juusela, HE1
Permi, JE1
Rusk, JI1
Sotarauta, MT1
Talja, MT1
Wuokko, EJ1
Mattila, MJ1
Henry, D1
Laddu, AR1
Filipek, M1
Suzuki, M1
Matsuoka, Y1
Kato, Y1
Maruyama, M1
Kobayashi, S1
Server, G1
Ruiz, JL1
Vidal, J1
Gallego, J1
Osca, JM1
Jiménez Cruz, JF1
Perrigot, M1
Vannier, A1
Bor, Y1
Hieble, JP2
Boyce, AJ1
Ashizawa, N1
Ushijima, H1
Nakayama, K1
Hayashi, E1
Honda, K1
Coppinger, SW1
Corcoran, MO1
Flannigan, M1
Baumann, M2
Kaminka, ME2
Zhirnikova, ML1
Vinarov, AZ2
Mashkovskiĭ, MD2
Pytel', IuA2
Gup, DI1
Zhirinkova, ML1
Aubry, ML1
James, S1
Greengrass, PM1
Burnstock, G1
Turner-Warwick, RT1
Davey, MJ1
Rowden, AM1
Mowers, RM1
Wozniak-Petrofsky, J1
Zalaznik, E1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT03314025]Phase 2158 participants (Anticipated)Interventional2017-10-06Recruiting
The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596]Phase 463 participants (Actual)Interventional2015-10-29Completed
Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of Org 3236 Tablets in Men With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia (BPH)[NCT00651807]Phase 216 participants (Actual)Interventional2008-03-31Terminated (stopped due to Business Reasons)
Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees[NCT00261729]210 participants (Anticipated)Interventional2004-07-31Completed
Prazosin for Noncombat Trauma PTSD[NCT00183430]20 participants (Actual)Interventional2003-10-31Terminated (stopped due to Insufficient Enrollment)
A Placebo-Controlled Trial of Prazosin vs. Paroxetine in Combat Stress-Related PTSD Nightmares and Sleep Disturbance[NCT00202449]59 participants (Actual)Interventional2004-07-31Terminated (stopped due to recruitment difficulties)
Medical Therapy of Prostatic Symptoms[NCT00021814]Phase 33,407 participants (Actual)Interventional1995-12-31Completed
Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy.[NCT01275521]Phase 3127 participants (Actual)Interventional2011-01-10Completed
A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH[NCT01736033]Phase 4545 participants (Actual)Interventional2012-02-29Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Recurring Distressing Dreams and Difficulty Falling and Staying Asleep Items of the CAPS

"Item B-2 recurrent distressing dreams of the event is a single item from teh Clinician Administered PTSD Scale (CAPS). The rating consists of two parts: Frequency plus Intensity. Symptom frequency rated 0 to 4. Symptom intensity rated 0 to 4. Frequency plus Intensity ratings equal the total score. The total minimum score = zero. The total maximum score = 8. A higher score is worse; a lower score is better. This outcome measure evaluates the change in score from Baseline to Week 8." (NCT00183430)
Timeframe: Baseline to Week 8

InterventionUnits on a Scale (Mean)
Prazosin-2.00
Placebo-1.09

Change in Sleep Assessed by the Pittsburgh Sleep Quality Index

Pittsburgh Sleep Quality Index is a self-report questionnaire assessing sleep quality and disturbances over a 1-month time interval. A global score is obtained by summing the seven component subscales (total score range: 0-21). A score of 5 or less indicates good sleep quality. A score of more than 5 indicates poor sleep quality. Change is measured from Baseline to Week 8. (NCT00183430)
Timeframe: Baseline to Week 8

InterventionUnits on a Scale (Mean)
Prazosin4
Placebo2.09

Clinical Global Impression of Change

The Clinical Global Impression of Change is a 7-point scale that rates global change compared to baseline (1=markedly improved, 2=moderately improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=moderately worse, 7=markedly worse). The Clinical Global Impression of Change is used to determine the impact of treatment effects on meaningful and distinct change in overall sense of well-being and functioning. This outcome measure evaluates change from Baseline to Week 8. (NCT00183430)
Timeframe: Baseline to Week 8

InterventionUnits on a Scale (Mean)
Prazosin2.33
Placebo3.27

Change in Combat Trauma-related Nightmares From the Clinician Administered PTSD Scale (CAPS) Recurrent Distressing Dreams Item at Week 12

"Item B-2 recurrent distressing dreams of the event is a single item from the Clinician Administered PTSD Scale. The rating consists of two parts: Frequency and Intensity. Symptom frequency rated 0 to 4. Symptom intensity rated 0 to 4. Frequency plus Intensity ratings equal the total score. A higher score is worse; a lower score is better. This outcome measure evaluates the change in score from Baseline to Week 12. Minimum = 0 Maximum = 8" (NCT00202449)
Timeframe: Baseline and Week 12

Interventionscale points (Mean)
Prazosin-1.29
Paroxetine-3.11
Placebo-2.67

Change in Global Trauma-related Symptom Severity and Functioning From the Clinical Global Impression of Change From Baseline to Week 12

The Clinical Global Impression of Change is a 7-point scale that rates global change compared to baseline (1=markedly improved, 2=moderately improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=moderately worse, 7=markedly worse). The CGIC is used to determine the impact of treatment effects on meaningful and distinct change in overall sense of well-being and functioning. This outcome measure evaluates change from baseline to Week 12. (NCT00202449)
Timeframe: Baseline to Week 12

Interventionscale points (Mean)
Prazosin3.14
Paroxetine2.11
Placebo2.33

Change in Sleep From the Pittsburgh Sleep Quality Index From Baseline to Week 12

Pittsburgh Sleep Quality Index is a self-report questionnaire assessing sleep quality and disturbances over a 1-month time interval. A global score is obtained by summing the seven component subscales (total score range: 0-21). A score of 5 or less indicates good sleep quality. A score of more than 5 indicates poor sleep quality. Change is measured from Baseline to Week 12. (NCT00202449)
Timeframe: Baseline to Week 12

Interventionscale points (Mean)
Prazosin-2.33
Paroxetine-6.44
Placebo-3.33

Reviews

52 reviews available for prazosin and Adenoma, Prostatic

ArticleYear
Pharmacological options in the treatment of benign prostatic hyperplasia.
    Journal of medicinal chemistry, 1997, Apr-25, Volume: 40, Issue:9

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlle

1997
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
    Canadian family physician Medecin de famille canadien, 2016, Volume: 62, Issue:9

    Topics: Adrenergic alpha-Antagonists; Dizziness; Doxazosin; Humans; Hypotension; Lower Urinary Tract Symptom

2016
[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
    Harefuah, 2008, Volume: 147, Issue:6

    Topics: Adrenergic alpha-Antagonists; Doxazosin; Evidence-Based Medicine; Humans; Male; Prazosin; Prostatic

2008
Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review.
    Systems biology in reproductive medicine, 2009, Volume: 55, Issue:4

    Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia; Randomized Controlled T

2009
[How effective is finasteride?].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:8

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Comb

2011
WITHDRAWN: Terazosin for benign prostatic hyperplasia.
    The Cochrane database of systematic reviews, 2011, Sep-07, Issue:9

    Topics: Adrenergic alpha-Antagonists; Aged; Antineoplastic Agents; Humans; Male; Middle Aged; Prazosin; Pros

2011
Advances in the design and synthesis of prazosin derivatives over the last ten years.
    Expert opinion on therapeutic targets, 2011, Volume: 15, Issue:12

    Topics: Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Drug Design; Humans; Hypertension;

2011
Terazosin for benign prostatic hyperplasia.
    The Cochrane database of systematic reviews, 2002, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Antineoplastic Agents; Humans; Male; Middle Aged; Prazosin; Pros

2002
[Alpha 1-adrenoceptor antagonists for treatment of prostatic hyperplsia].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 11

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Androgen Antagonists; Drug Th

2002
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    The Journal of urology, 2003, Volume: 169, Issue:4

    Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostate; Prostatic Hype

2003
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Current urology reports, 2003, Volume: 4, Issue:4

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug The

2003
[Pharmacologic treatment of benign prostatic hyperplasia].
    Orvosi hetilap, 2003, Sep-14, Volume: 144, Issue:37

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasterid

2003
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    The Prostate, 2004, Apr-01, Volume: 59, Issue:1

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans;

2004
Treatment and pharmacologic management of BPH in the context of common comorbidities.
    The American journal of managed care, 2006, Volume: 12, Issue:5 Suppl

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Co

2006
[Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension].
    Zhonghua nan ke xue = National journal of andrology, 2007, Volume: 13, Issue:9

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Huma

2007
FPIN's clinical inquiries. Medical treatment of benign prostatic hyperplasia.
    American family physician, 2008, Mar-01, Volume: 77, Issue:5

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Antineoplastic Agents; Enzyme

2008
Alpha-blockers in the treatment of benign prostatic hypertrophy: physiological basis and review of the problem.
    European urology, 1984, Volume: 10, Issue:5

    Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Double-Blind Method; Humans; Labetalol; Male

1984
[Terazosine in the treatment of benign prostatic hypertrophy].
    Journal d'urologie, 1993, Volume: 99, Issue:6

    Topics: Administration, Oral; Adrenergic alpha-Antagonists; Drug Therapy, Combination; Flutamide; Humans; Ma

1993
[Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Der Urologe. Ausg. A, 1995, Volume: 34, Issue:1

    Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Receptors, A

1995
Therapeutic controversies: clinical treatment of benign prostatic hyperplasia.
    The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:3

    Topics: Adrenergic alpha-Antagonists; Cholestenone 5 alpha-Reductase; Clinical Trials as Topic; Drug Therapy

1995
Clinical research criteria: response criteria for evaluating efficacy of treatments for benign prostatic hypertrophy.
    British journal of urology, 1995, Volume: 76 Suppl 1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Drug Combinations; Humans; Laser Therapy; Male; Middl

1995
[New in Austria approved specialty drugs and new knowledge regarding currently available specialty drugs. Uroflo].
    Wiener klinische Wochenschrift, 1995, Volume: 107, Issue:15

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Dose-Response Relationship, D

1995
The role of alpha 1-blockade in benign prostatic hyperplasia.
    Journal of clinical pharmacology, 1993, Volume: 33, Issue:9

    Topics: Adrenergic alpha-Antagonists; Aging; Clinical Trials as Topic; Humans; Male; Phenoxybenzamine; Prazo

1993
Medical therapy for benign prostatic hyperplasia.
    Urology, 1993, Volume: 42, Issue:5

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androgen Antagonists; Anilides; Clinical

1993
Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
    European urology, 1996, Volume: 29, Issue:2

    Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Doxazosin; Half-Life; Humans

1996
Measures of Proscar, Hytrin, and Cardura side effects.
    Neurourology and urodynamics, 1997, Volume: 16, Issue:1

    Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia

1997
Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.
    Drugs & aging, 1997, Volume: 10, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Pract

1997
Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.
    Southern medical journal, 1997, Volume: 90, Issue:5

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Clinical Trials as Topic; Dizziness; Humans;

1997
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
    Revista clinica espanola, 1997, Volume: 197, Issue:5

    Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prosta

1997
[Terazosin].
    Deutsche medizinische Wochenschrift (1946), 1998, Apr-09, Volume: 123, Issue:15

    Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia

1998
Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
    British journal of urology, 1998, Volume: 81 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Hormones; Humans; Male; Patient S

1998
Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients.
    British journal of urology, 1998, Volume: 81 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Aged; Female; Humans; Hypertension; Male; Multicenter Studies as Topic

1998
Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
    Urology, 1998, Volume: 51, Issue:6

    Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Male; Prazosin; Prostatic

1998
Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    PharmacoEconomics, 1997, Volume: 11, Issue:2

    Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia

1997
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    European urology, 1999, Volume: 36, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizzines

1999
Medical therapy for benign prostatic hyperplasia: a review of the literature.
    European urology, 2000, Volume: 38, Issue:1

    Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic H

2000
[Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2000, Volume: 116, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Animals; Binding, Competitive; Dogs; Humans; Male; Naphthalenes;

2000
Development of a new in vitro model for the study of benign prostatic hyperplasia.
    The Prostate. Supplement, 2000, Volume: 9

    Topics: Cell Differentiation; Coculture Techniques; Epithelial Cells; Humans; Male; Microscopy, Electron; Mo

2000
Clinical perspective on apoptosis in the management of the BPH patient.
    The Prostate. Supplement, 2000, Volume: 9

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Humans; Male; Musc

2000
[Drugs for the treatment of benign prostatic hypertrophy].
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2000, Volume: 52, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; D

2000
Alpha-blockers in hypertension: growing recognition as first line therapy.
    The Journal of the Association of Physicians of India, 1998, Volume: Suppl 1

    Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Lipid Metabolism; Male; Prazosin; Prostatic Hype

1998
Benign prostatic hyperplasia. The Saudi perspective in the year 2000.
    Saudi medical journal, 2000, Volume: 21, Issue:10

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Age Distribution; Age of Onset; Aged; Fi

2000
Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia.
    Urology, 2001, Volume: 58, Issue:5

    Topics: Adrenergic alpha-Antagonists; Aged; Bayes Theorem; Humans; Male; Middle Aged; Prazosin; Prostatic Hy

2001
Terazosin, doxazosin, and prazosin: current clinical experience.
    Urology, 2001, Volume: 58, Issue:6 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prostatic

2001
5alpha-reductase inhibitors: what role should they play?
    Urology, 2001, Volume: 58, Issue:6 Suppl 1

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Therapy, C

2001
Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.
    Current urology reports, 2000, Volume: 1, Issue:2

    Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; T

2000
Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.
    British journal of urology, 1992, Volume: 70 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Male; Prazosin; Prostatic Hyperplasi

1992
[Prostatic adenoma: new drugs, new surgical techniques].
    Medizinische Monatsschrift fur Pharmazeuten, 1992, Volume: 15, Issue:12

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androstenes; Azasteroids; Cystoscopes; D

1992
Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.
    The Prostate. Supplement, 1990, Volume: 3

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Brimonidine Tartrate; Carbachol; Humans; Ma

1990
The efficacy and safety of terazosin for the treatment of symptomatic BPH.
    The Prostate, 1991, Volume: 18, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Humans; Male; Middle Aged; Or

1991
Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy.
    Urology, 1988, Volume: 32, Issue:6 Suppl

    Topics: Adrenergic alpha-Antagonists; Humans; Male; Phenoxybenzamine; Prazosin; Prostate; Prostatic Hyperpla

1988
Alpha-adrenoceptor inhibitors in the treatment of benign prostatic hyperplasia.
    The American journal of medicine, 1989, Aug-16, Volume: 87, Issue:2A

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prostati

1989

Trials

88 trials available for prazosin and Adenoma, Prostatic

ArticleYear
A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia.
    Urology journal, 2021, Apr-11, Volume: 18, Issue:3

    Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Antihypertensive Agents; Carvedilol; Cross-Over Studi

2021
Comparison of Anti BPH capsule (herbal) and Terazosin HCl in the treatment of benign prostate hyperplasia.
    Pakistan journal of pharmaceutical sciences, 2017, Volume: 30, Issue:1 Suppl

    Topics: Adult; Aged; Aged, 80 and over; Capsules; Humans; Male; Middle Aged; Plant Extracts; Plant Preparati

2017
[Efficacy and safety of Tonglin Powder in the treatment of benign prostatic hyperplasia].
    Zhonghua nan ke xue = National journal of andrology, 2016, Volume: 22, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Drugs, Chinese Herbal; Humans; Male; Middle Aged; Prazosin; Prostati

2016
Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
    Acta medica Okayama, 2013, Volume: 67, Issue:4

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Doxazos

2013
Pumpkin seed oil (prostafit) or prazosin? Which one is better in the treatment of symptomatic benign prostatic hyperplasia.
    JPMA. The Journal of the Pakistan Medical Association, 2014, Volume: 64, Issue:6

    Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cucurbita; Humans; Male; Middle Aged; Plant Oils; Pra

2014
[Peculiarities of clinical course, diagnostics and treatment of overactive bladder in men older than 60 years].
    Advances in gerontology = Uspekhi gerontologii, 2014, Volume: 27, Issue:3

    Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Prazosin; Prostatic H

2014
[Efficacy of electroacupuncture in treating 93 patients with benign prostatic hyperplasia].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2008, Volume: 28, Issue:11

    Topics: Aged; Aged, 80 and over; Electroacupuncture; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperpla

2008
[Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention].
    Zhonghua nan ke xue = National journal of andrology, 2009, Volume: 15, Issue:5

    Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug T

2009
Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches.
    Complementary therapies in medicine, 2010, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents; Humans; Logistic Models; Male; Medicine; Medicine, Chinese Traditional;

2010
Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
    The Journal of urology, 2003, Volume: 170, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Human

2003
Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.
    International journal of urology : official journal of the Japanese Urological Association, 2003, Volume: 10, Issue:11

    Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Hypertension; Male; Prazosin; Prostatic

2003
Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:5

    Topics: Clinical Trials as Topic; Doxazosin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Com

2004
Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
    Urologia internationalis, 2004, Volume: 73, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Doxazosin; Humans; Male; Middle Aged; Prazos

2004
Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia.
    Journal of the Indian Medical Association, 2005, Volume: 103, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Phytotherapy; Plants, Medicinal; Praz

2005
Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Chinese medical journal, 2007, Mar-05, Volume: 120, Issue:5

    Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cresols; Drug Therapy, Combination; Humans

2007
Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
    Clinical therapeutics, 2007, Volume: 29, Issue:4

    Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Over Studies; Dizziness; Drugs, Generic; Edema;

2007
[Comparison of different drugs on the treatment of benign prostate hyperplasia].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2007, Jul-15, Volume: 45, Issue:14

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes;

2007
Alpha-blockers in the treatment of benign prostatic hypertrophy: physiological basis and review of the problem.
    European urology, 1984, Volume: 10, Issue:5

    Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Double-Blind Method; Humans; Labetalol; Male

1984
Effects of prazosin in patients with benign prostatic obstruction.
    The Journal of urology, 1983, Volume: 130, Issue:2

    Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic

1983
Comparative study of selective alpha 1-adrenoceptor blockade versus surgery in the treatment of prostatic obstruction.
    British journal of urology, 1993, Volume: 72, Issue:5 Pt 2

    Topics: Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatectomy; Pr

1993
Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
    British journal of urology, 1993, Volume: 72, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Age

1993
Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
    Archives of family medicine, 1993, Volume: 2, Issue:9

    Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hy

1993
Use of terazosin in prostatodynia and validation of a symptom score questionnaire.
    Urology, 1994, Volume: 43, Issue:4

    Topics: Adrenergic alpha-Antagonists; Adult; Humans; Logistic Models; Male; Middle Aged; Pain; Pain Measurem

1994
Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
    Urology, 1994, Volume: 44, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind M

1994
Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial.
    The Journal of family practice, 1994, Volume: 39, Issue:2

    Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Middle Aged; Prazosin; Primary Health Care

1994
Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group.
    Urology, 1995, Volume: 45, Issue:3

    Topics: Adrenergic alpha-Antagonists; Blood Pressure; Follow-Up Studies; Humans; Male; Prazosin; Prostatic H

1995
Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
    Urology, 1995, Volume: 46, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Decision Trees; Enzyme Inhibitors; Finasteride; Health Care Cost

1995
Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One).
    International urology and nephrology, 1995, Volume: 27, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Doxazosin; Humans; Male; Midd

1995
[Evaluation of prazosin in the treatment of benign hypertrophy of the prostate. A case-control study].
    Actas urologicas espanolas, 1993, Volume: 17, Issue:7

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperp

1993
The effect of prazosin on patients with symptoms of benign prostatic hypertrophy.
    Australian family physician, 1993, Volume: 22, Issue:7

    Topics: Aged; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperpl

1993
Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
    European urology, 1995, Volume: 28, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Doxazosin; Drug Administration Schedule; Humans;

1995
Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two).
    International urology and nephrology, 1995, Volume: 27, Issue:4

    Topics: Acid Phosphatase; Adrenergic alpha-Antagonists; Creatinine; Doxazosin; Humans; Male; Prazosin; Prost

1995
The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
    Urology, 1996, Volume: 47, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Humans; Male; Middle Ag

1996
The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia.
    Urology, 1996, Volume: 47, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Cost-Benefit Analysis;

1996
Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
    The Journal of urology, 1996, Volume: 155, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urin

1996
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
    Urology, 1996, Volume: 47, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Canada; Double-Blind Me

1996
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    The New England journal of medicine, 1996, Aug-22, Volume: 335, Issue:8

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combinatio

1996
The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group.
    European urology, 1996, Volume: 30, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Mid

1996
Terazosin vs finasteride for BPH.
    The Journal of family practice, 1996, Volume: 43, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Combinations; Enzyme Inhibitors; Finaste

1996
Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
    Urology, 1997, Volume: 49, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prospect

1997
Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates.
    Urology, 1997, Volume: 49, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prosta

1997
Influence of prostate size on terazosin efficacy.
    International journal of urology : official journal of the Japanese Urological Association, 1997, Volume: 4, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prosta

1997
Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.
    Urology, 1997, Volume: 50, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Longitudinal Stu

1997
Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
    British journal of urology, 1997, Volume: 80, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Dose-Response Relationship, D

1997
[Therapy of benign prostatic hyperplasia: terazosin or finasteride?].
    Praxis, 1997, Aug-20, Volume: 86, Issue:34

    Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Pra

1997
A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing.
    European urology, 1998, Volume: 33, Issue:5

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Blood Pressure; Blood Pressure Moni

1998
The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    The Journal of urology, 1998, Volume: 160, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combinatio

1998
Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
    British journal of urology, 1998, Volume: 82, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressur

1998
Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia.
    The Journal of urology, 1999, Volume: 161, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Diathermy; Humans; Male; Microwaves; Middle Aged; Prazosin; Pros

1999
Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359.
    The Prostate, 1999, Jun-01, Volume: 39, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Finas

1999
Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications.
    Urology, 1999, Volume: 54, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Hypertension; Male; Prazosin; Prostatic

1999
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Journal of medicine, 1998, Volume: 29, Issue:5-6

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Dose-Response Relations

1998
[Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy].
    Hinyokika kiyo. Acta urologica Japonica, 1999, Volume: 45, Issue:12

    Topics: Aged; Coronary Disease; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Prazosin; Prostatic Hype

1999
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.
    The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Chronic Disease; Combat Disorders; Comorbidity;

2000
The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study.
    The Journal of urology, 2000, Volume: 163, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia

2000
A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients.
    BJU international, 2000, Volume: 85, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prazosi

2000
Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.
    International journal of urology : official journal of the Japanese Urological Association, 2000, Volume: 7, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Prazosin; Prostatic Hyperplasia; S

2000
[Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2000, Volume: 10, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Ambulatory Care; Double-Blind Method; Humans;

2000
[Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2000, Volume: 10, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Humans; Male; Practice Patterns, Physicians'; P

2000
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months.
    Urology, 2001, Volume: 57, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Follow-Up Studies; Hum

2001
[The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy].
    Hinyokika kiyo. Acta urologica Japonica, 2001, Volume: 47, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prazos

2001
[A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
    Hinyokika kiyo. Acta urologica Japonica, 2001, Volume: 47, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prazosi

2001
The efficacy of terazosin for treating benign prostatic hyperplasia: a multicentre clinical trial.
    BJU international, 2002, Volume: 89, Issue:7

    Topics: Adrenergic alpha-Antagonists; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prazosin;

2002
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
    The Journal of urology, 1992, Volume: 148, Issue:5

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prazosin;

1992
Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up.
    British journal of urology, 1992, Volume: 70 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Follow-Up Studies; Human

1992
Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial.
    British journal of urology, 1992, Volume: 70 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Aged; Clinical Protocols; Double-Blind Method; Humans; Male; Middle Ag

1992
Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.
    British journal of urology, 1992, Volume: 70 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Male; Prazosin; Prostatic Hyperplasi

1992
Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy.
    British journal of urology, 1992, Volume: 70 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prosta

1992
The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
    The Journal of urology, 1992, Volume: 147, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Patient Compliance

1992
Efficacy of terazosin in patients with benign prostatic hyperplasia.
    European urology, 1992, Volume: 21, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Drug Evaluation; Humans; Male; Pra

1992
[A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
    Hinyokika kiyo. Acta urologica Japonica, 1992, Volume: 38, Issue:7

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M

1992
A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia.
    British journal of urology, 1992, Volume: 70, Issue:3

    Topics: Adolescent; Adult; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperpl

1992
Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial.
    The Prostate. Supplement, 1990, Volume: 3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Age

1990
Clinical overview of prazosin in the treatment of prostatic obstruction.
    Urologia internationalis, 1990, Volume: 45 Suppl 1

    Topics: Aged; Clinical Trials as Topic; Humans; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Prazo

1990
Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study.
    Urologia internationalis, 1990, Volume: 45 Suppl 1

    Topics: Aged; Aged, 80 and over; Alanine; Double-Blind Method; Drug Combinations; Glutamates; Glycine; Human

1990
A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction.
    Urologia internationalis, 1990, Volume: 45 Suppl 1

    Topics: Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperpl

1990
A multicenter, double-blind, placebo-controlled trial of the efficacy of prazosin in the treatment of dysuria associated with benign prostatic hypertrophy.
    Urologia internationalis, 1990, Volume: 45 Suppl 1

    Topics: Double-Blind Method; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prazosin; Prostatic Hy

1990
A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
    The Journal of urology, 1990, Volume: 144, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Drug Administration Schedule; Humans; Male; Midd

1990
Efficacy and side-effects of prazosin as a symptomatic treatment of benign prostatic obstruction.
    Scandinavian journal of urology and nephrology, 1991, Volume: 25, Issue:1

    Topics: Aged; Blood Pressure; Double-Blind Method; Heart Rate; Humans; Male; Middle Aged; Prazosin; Prostati

1991
The efficacy and safety of terazosin for the treatment of symptomatic BPH.
    The Prostate, 1991, Volume: 18, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Humans; Male; Middle Aged; Or

1991
[Treatment of obstruction caused by prostatic hypertrophy with prazosin. 1-year follow-up].
    Archivos espanoles de urologia, 1991, Volume: 44, Issue:9

    Topics: Aged; Drug Evaluation; Follow-Up Studies; Humans; Hypotension, Orthostatic; Male; Middle Aged; Patie

1991
Prazosin in the treatment of prostatic obstruction. A placebo-controlled study.
    British journal of urology, 1987, Volume: 60, Issue:2

    Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic

1987
Effects of prazosin and carbachol in patients with benign prostatic obstruction.
    Scandinavian journal of urology and nephrology, 1988, Volume: 22, Issue:1

    Topics: Aged; Carbachol; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Prazosin

1988
Clinical experience: symptomatic management of BPH with terazosin.
    Urology, 1988, Volume: 32, Issue:6 Suppl

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Multicenter Studies as Topic; Placebos; Prazosin;

1988
Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
    Urology, 1988, Volume: 32, Issue:6 Suppl

    Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Muscl

1988
Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
    Urology, 1988, Volume: 32, Issue:6 Suppl

    Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Muscl

1988
Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
    Urology, 1988, Volume: 32, Issue:6 Suppl

    Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Muscl

1988
Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
    Urology, 1988, Volume: 32, Issue:6 Suppl

    Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Muscl

1988
Alpha-adrenoceptor inhibitors in the treatment of benign prostatic hyperplasia.
    The American journal of medicine, 1989, Aug-16, Volume: 87, Issue:2A

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prostati

1989
Coping with prostatic symptoms.
    The Practitioner, 1988, Jun-08, Volume: 232, Issue:1450

    Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Male; Prazosin; Prostatic Hyperplasia; Urinat

1988
Effects of prazosin in men with symptoms of bladder neck obstruction and a non-hyperplastic prostate.
    Scandinavian journal of urology and nephrology, 1989, Volume: 23, Issue:4

    Topics: Adult; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urinary Blad

1989

Other Studies

132 other studies available for prazosin and Adenoma, Prostatic

ArticleYear
N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.
    Journal of medicinal chemistry, 1997, Aug-15, Volume: 40, Issue:17

    Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Amid

1997
Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.
    Journal of medicinal chemistry, 1998, Dec-17, Volume: 41, Issue:26

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Binding, Competitive

1998
Design and synthesis of novel dihydropyridine alpha-1a antagonists.
    Bioorganic & medicinal chemistry letters, 1999, Oct-04, Volume: 9, Issue:19

    Topics: Adrenergic Antagonists; Animals; Calcium Channels; Dihydropyridines; Dogs; Humans; Male; Molecular S

1999
Pharmacophore-based design, synthesis, biological evaluation, and 3D-QSAR studies of aryl-piperazines as alpha(1)-adrenoceptor antagonists.
    Bioorganic & medicinal chemistry letters, 2005, Jul-01, Volume: 15, Issue:13

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Databases, Factual; Drug Desi

2005
Evaluation of syncope association with α
    Die Pharmazie, 2019, 12-01, Volume: 74, Issue:12

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Midd

2019
Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia.
    Korean journal of urology, 2014, Volume: 55, Issue:12

    Topics: Aged; Case-Control Studies; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Metabolic Syndr

2014
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
    The Canadian journal of urology, 2015, Volume: 22, Issue:4

    Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug

2015
Assessment of Urologists' Knowledge of Intraoperative Floppy Iris Syndrome.
    Urology, 2016, Volume: 97

    Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Competence; Fellowships and Scholarships; Female;

2016
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
    Journal of cataract and refractive surgery, 2008, Volume: 34, Issue:7

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosi

2008
Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume.
    Journal of Korean medical science, 2008, Volume: 23, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Logistic Models; Male; Middle Aged; P

2008
A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results.
    BJU international, 2009, Volume: 104, Issue:1

    Topics: Acetamides; Adrenergic alpha-Antagonists; Aged; Behavior Therapy; Benzhydryl Compounds; Combined Mod

2009
Iris morphologic changes related to alpha(1)-adrenergic receptor antagonists implications for intraoperative floppy iris syndrome.
    Ophthalmology, 2009, Volume: 116, Issue:5

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cross-Sectional Studies

2009
Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity.
    BJU international, 2009, Volume: 104, Issue:11

    Topics: Adrenergic alpha-Antagonists; Amlodipine; Animals; Calcium Channel Blockers; Drug Therapy, Combinati

2009
Development and validation of an Arabic version of the International Prostate Symptom Score.
    BJU international, 2010, Volume: 105, Issue:10

    Topics: Adrenergic alpha-Antagonists; Humans; Language; Male; Middle Aged; Prazosin; Prostatic Hyperplasia;

2010
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
    The Journal of urology, 2010, Volume: 183, Issue:5

    Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Redu

2010
Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
    Urology, 2011, Volume: 77, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Blood Coagulation; Blood Pressure; Brachial Artery; Doxazosin; E

2011
Anti-angiogenic effects and mechanism of prazosin.
    The Prostate, 2011, Jun-15, Volume: 71, Issue:9

    Topics: Adrenergic alpha-1 Receptor Antagonists; Angiogenesis Inhibitors; Apoptosis; Blotting, Western; Cell

2011
Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.
    Journal of pharmacy practice, 2012, Volume: 25, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combinati

2012
Management of men with a first episode of acute urinary retention due to benign prostatic enlargement.
    The Ceylon medical journal, 2001, Volume: 46, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prospect

2001
Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
    Urologia internationalis, 2002, Volume: 69, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combine

2002
Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
    Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urin

2003
Herbal and vitamin supplement use in a prostate cancer screening population.
    Urology, 2004, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietar

2004
A current review of medical therapy for benign prostatic hyperplasia.
    The Journal of the American Osteopathic Association, 2004, Volume: 104, Issue:2 Suppl 2

    Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Dr

2004
[Effect of nitric oxide donor and alpha1-receptor antagonist on proliferation/apoptosis of hyperplastic prostatic stromal cells in vitro].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2004, Feb-22, Volume: 42, Issue:4

    Topics: Adrenergic alpha-Antagonists; Apoptosis; Dose-Response Relationship, Drug; Drug Synergism; Humans; I

2004
Meta-analysis: creating a level playing field for the patient with symptomatic benign prostatic hyperplasia?
    BJU international, 2004, Volume: 94, Issue:1

    Topics: Antineoplastic Agents; Catheter Ablation; Finasteride; Humans; Male; Meta-Analysis as Topic; Prazosi

2004
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Scandinavian journal of urology and nephrology, 2004, Volume: 38, Issue:5

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin;

2004
Baroreceptor mediated blood pressure regulation is not affected during dose dependent inhibition of prostatic contractions by terazosin.
    Indian journal of physiology and pharmacology, 2004, Volume: 48, Issue:4

    Topics: Animals; Baroreflex; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Male; Muscle Contractio

2004
alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction.
    BJU international, 2006, Volume: 97, Issue:5

    Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Pra

2006
Significance of nocturnal hesitancy in treatment of men with lower urinary tract symptoms.
    Urology, 2006, Volume: 67, Issue:5

    Topics: Adrenergic alpha-Antagonists; Humans; Male; Polyuria; Prazosin; Prospective Studies; Prostatic Hyper

2006
A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia.
    The Journal of urology, 2006, Volume: 176, Issue:3

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Disease Models, Anim

2006
Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Bangladesh Medical Research Council bulletin, 2005, Volume: 31, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Bangladesh; Enzyme Inhibitors; Finasteride; Humans; Male; Middle

2005
Pumpkin seed oil and phytosterol-F can block testosterone/prazosin-induced prostate growth in rats.
    Urologia internationalis, 2006, Volume: 77, Issue:3

    Topics: Animals; Body Weight; Cucurbita; Disease Models, Animal; Drug Therapy, Combination; Male; Phytostero

2006
Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study.
    International urology and nephrology, 2007, Volume: 39, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Pra

2007
Lichenoid drug eruption to terazosin.
    The British journal of dermatology, 2008, Volume: 158, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged, 80 and over; Drug Eruptions; Humans; Lichenoid Eruptions; Male;

2008
Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals.
    International urology and nephrology, 2008, Volume: 40, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prostate

2008
Acute intoxication with terazosin.
    The American journal of emergency medicine, 2008, Volume: 26, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Bradycardia; Drug Overdose; Electrocardiography; Humans; Male; P

2008
[Pharmacological characteristics of smooth muscle in prostatic hyperplastic nodule and significance of clinical aspects].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1983, Volume: 74, Issue:12

    Topics: Aged; Dinoprost; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth;

1983
Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia.
    The Journal of urology, 1984, Volume: 132, Issue:6

    Topics: Binding Sites; Binding, Competitive; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Quinaz

1984
Role of intracellular Ca2+ stores in smooth muscle contractions of the guinea pig vas deferens.
    Urological research, 1993, Volume: 21, Issue:5

    Topics: Adrenergic alpha-Antagonists; Animals; Calcium; Calcium Channels; Guinea Pigs; Humans; In Vitro Tech

1993
Terazosin for benign prostatic hyperplasia.
    The Medical letter on drugs and therapeutics, 1994, Feb-18, Volume: 36, Issue:916

    Topics: Adrenergic alpha-Antagonists; Humans; Hypotension, Orthostatic; Male; Prazosin; Prostatic Hyperplasi

1994
Men's health issues.
    Archives of family medicine, 1993, Volume: 2, Issue:9

    Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic

1993
Terazosin now indicated for benign prostatic hyperplasia.
    American journal of hospital pharmacy, 1994, Jan-01, Volume: 51, Issue:1

    Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia

1994
Effects of dicentrine, a novel alpha 1-adrenoceptor antagonist, on human hyperplastic prostates.
    European journal of pharmacology, 1994, Jan-24, Volume: 252, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aporphines; Binding Sites; Dose-Response Rela

1994
Effect of terazosin on urine storage and voiding in the aging male with prostatism.
    Neurourology and urodynamics, 1994, Volume: 13, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Prazosin; Prosta

1994
Quantitative-comparative histology of prostatic adenomas in medically and surgically treated patients.
    International urology and nephrology, 1994, Volume: 26, Issue:4

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Fatty Alcohols; Humans; Male; Muscle, Smooth; Plant E

1994
[Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
    Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma, 1994, Volume: 65, Issue:1-2

    Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostati

1994
Alpha 1-adrenoceptor subtypes in the human prostate.
    British journal of urology, 1994, Volume: 74, Issue:5

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Aminoquinolines; Dioxanes; Dose-Response Rela

1994
Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies.
    British journal of urology, 1994, Volume: 74, Issue:5

    Topics: Adrenergic alpha-Antagonists; Binding, Competitive; Clonidine; Dioxanes; Dose-Response Relationship,

1994
Terazosin for BPH.
    The Journal of family practice, 1995, Volume: 40, Issue:3

    Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Hypertension; Male; Prazosin; Prosta

1995
[Terazosin in the treatment of benign prostatic hypertrophy].
    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 1995, Volume: 67, Issue:1

    Topics: Adrenergic alpha-Antagonists; Humans; Male; Multicenter Studies as Topic; Prazosin; Prostatic Hyperp

1995
Hytrin treatment of hypertension and benign prostatic hyperplasia.
    ANNA journal, 1995, Volume: 22, Issue:3

    Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia

1995
The medication minute: terazosin.
    Urologic nursing, 1995, Volume: 15, Issue:2

    Topics: Adrenergic alpha-Antagonists; Humans; Male; Patient Education as Topic; Prazosin; Prostatic Hyperpla

1995
Combination drug therapy for benign prostatic hyperplasia.
    JAMA, 1995, Jul-26, Volume: 274, Issue:4

    Topics: Adrenergic alpha-Antagonists; Drug Synergism; Drug Therapy, Combination; Finasteride; Humans; Male;

1995
Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate.
    The Journal of urology, 1993, Volume: 149, Issue:2

    Topics: Adrenergic alpha-Antagonists; Animals; Dogs; Dose-Response Relationship, Drug; Epinephrine; Male; Mu

1993
Transurethral resection of the prostate: still the gold standard?
    Canadian journal of surgery. Journal canadien de chirurgie, 1993, Volume: 36, Issue:1

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Androstenes; Azasteroids; C

1993
[Pharma-clinics. Drug of the month. Terazosine (Hytrin)].
    Revue medicale de Liege, 1995, Volume: 50, Issue:12

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Hypertension; Male; Middle Aged; Praz

1995
Treatment of benign prostatic hyperplasia.
    The New England journal of medicine, 1996, Aug-22, Volume: 335, Issue:8

    Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Mal

1996
Analysis of the relative biomechanical effects of alpha 1 and alpha 2 antagonists in modifying the compliance of the prostate and micturition parameters of the hormonally manipulated male rat.
    Neurourology and urodynamics, 1996, Volume: 15, Issue:1

    Topics: Adrenergic alpha-Antagonists; Animals; Dihydrotestosterone; Drug Combinations; Estradiol; Imidazoles

1996
Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate.
    Journal of autonomic pharmacology, 1996, Volume: 16, Issue:1

    Topics: Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Cerebral Cortex; Humans; Kidney; Male;

1996
Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation.
    European journal of pharmacology, 1996, Jun-03, Volume: 305, Issue:1-3

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Aged; Calcium Channel Blockers; Electric St

1996
Study provides head-to-head comparison of terazosin, finasteride.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Oct-15, Volume: 53, Issue:20

    Topics: Adrenergic alpha-Antagonists; Cholestenone 5 alpha-Reductase; Drug Therapy, Combination; Finasteride

1996
Terazosin, finasteride, or both in benign prostatic hyperplasia.
    The New England journal of medicine, 1997, Jan-23, Volume: 336, Issue:4

    Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia; Urodynamics

1997
Terazosin, finasteride, or both in benign prostatic hyperplasia.
    The New England journal of medicine, 1997, Jan-23, Volume: 336, Issue:4

    Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hypotensio

1997
Radioligand-binding analysis of human prostatic alpha-1 adrenoreceptor density following transurethral microwave therapy.
    British journal of urology, 1996, Volume: 78, Issue:6

    Topics: Aged; Humans; Male; Microwaves; Prazosin; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Uri

1996
Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs.
    Pharmacology, 1996, Volume: 53, Issue:6

    Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Doxazosin; Male; Prazosin; Prostatic Hy

1996
alpha-receptor blockade for benign prostatic hyperplasia: uses and problems in a developing country.
    British journal of urology, 1997, Volume: 79, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Heart Diseases; Humans; Hypertension; Male; M

1997
Glans hyperemia after penile revascularization: a late complication following alpha-1-receptor blockade for benign prostatic hyperplasia.
    Urologia internationalis, 1997, Volume: 58, Issue:1

    Topics: Adrenergic alpha-Antagonists; Anastomosis, Surgical; Epigastric Arteries; Humans; Hyperemia; Impoten

1997
[Ureteral jet in patients with benign prostatic hypertrophy: prognostic evaluation during single and combined therapy].
    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 1996, Volume: 68, Issue:5 Suppl

    Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Mal

1996
Alpha-1 adrenoceptor subtypes (high, low) in human benign prostatic hypertrophy tissue according to the affinities for prazosin.
    The Prostate, 1997, Jun-01, Volume: 31, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Prazosin; Prostatic Hyperplasia; Receptors, Adrene

1997
What is the best medical treatment for benign prostate hyperplasia?
    Canadian family physician Medecin de famille canadien, 1997, Volume: 43

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Therapy, C

1997
Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction.
    Urology, 1997, Volume: 50, Issue:1

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Laser Therapy; Male; Microwaves; Middle Aged; Prazosin;

1997
Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 282, Issue:2

    Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals

1997
KMD-3213, a novel alpha1A-adrenoceptor antagonist, potently inhibits the functional alpha1-adrenoceptor in human prostate.
    European journal of pharmacology, 1997, Jul-16, Volume: 331, Issue:1

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Dose-Response Relationship, D

1997
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
    Journal of medicinal chemistry, 1997, Sep-26, Volume: 40, Issue:20

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dogs; Humans; Indole

1997
Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Urology, 1997, Volume: 50, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Enzyme Inhibitors; Finasteri

1997
Neurohormonal stimulation of histamine release from neuroendocrine cells of the human adenomatous prostate.
    The Prostate, 1998, Jan-01, Volume: 34, Issue:1

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Carba

1998
The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
    British journal of urology, 1997, Volume: 80, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Doxazosin; Humans; Male; Praz

1997
Chronology and urodynamic characterization of micturition in neurohormonally induced experimental prostate growth in the rat.
    Neurourology and urodynamics, 1998, Volume: 17, Issue:1

    Topics: Adrenergic alpha-Antagonists; Animals; Chronic Disease; Dihydrotestosterone; Disease Models, Animal;

1998
Alpha1-adrenoceptors in testosterone-induced prostatic hypertrophy.
    European journal of pharmacology, 1998, Jan-02, Volume: 341, Issue:1

    Topics: Animals; Antineoplastic Agents, Hormonal; Male; Polymerase Chain Reaction; Prazosin; Prostate; Prost

1998
In vivo receptor binding of novel alpha1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia.
    Life sciences, 1998, Volume: 62, Issue:17-18

    Topics: Adrenergic alpha-Antagonists; Animals; Cresols; Indoles; Male; Prazosin; Prostate; Prostatic Hyperpl

1998
Severe cutaneous reaction due to terazosin.
    Lancet (London, England), 1998, Jul-18, Volume: 352, Issue:9123

    Topics: Adrenergic alpha-Antagonists; Drug Eruptions; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperpl

1998
Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future.
    British journal of urology, 1998, Volume: 82, Issue:1

    Topics: Adrenergic alpha-Agonists; Humans; Male; Prazosin; Prostatic Hyperplasia

1998
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
    The Journal of urology, 1999, Volume: 161, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Doxazosin; Humans;

1999
Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study.
    Clinical therapeutics, 1999, Volume: 21, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Decision Trees; Enzyme Inhibitors; Finasteride; Humans; Male; Mi

1999
By the way, doctor... I'm 78 and have more and more difficulty urinating. I get up three times a night - sometimes more - to go to the bathroom and it takes me a while to start urinating and even longer to stop. I know that this is probably a prostate pro
    Harvard health letter, 1999, Volume: 24, Issue:12

    Topics: Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulf

1999
Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Jul-01, Volume: 56, Issue:13

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Drug Prescriptions; Humans;

1999
Diet and herbs for BPH?
    RN, 2000, Volume: 63, Issue:2

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Phytoth

2000
Does induction of apoptosis contribute to the overall clinical profile of terazosin? Introduction.
    The Prostate. Supplement, 2000, Volume: 9

    Topics: Apoptosis; Cell Division; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Stromal Cells

2000
Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
    The Prostate. Supplement, 2000, Volume: 9

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Biopsy; Cell Divis

2000
Transurethral resection of the prostate: failure patterns and surgical outcomes in patients with symptoms refractory to alpha-antagonists.
    Southern medical journal, 2000, Volume: 93, Issue:12

    Topics: Adrenergic alpha-Antagonists; Aged; Comorbidity; Doxazosin; Humans; Louisiana; Male; Postoperative C

2000
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
    The Prostate, 2001, Jan-01, Volume: 46, Issue:1

    Topics: Adrenergic alpha-Antagonists; Antibodies, Monoclonal; Apoptosis; Cell Division; Drug Combinations; E

2001
Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia.
    International journal of urology : official journal of the Japanese Urological Association, 2001, Volume: 8, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Biopsy; Humans; Magnetic Resonance Imaging; M

2001
The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2001, Volume: 68, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M

2001
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations.
    Journal of clinical epidemiology, 2001, Volume: 54, Issue:5

    Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Bias; Cardiovascular Diseas

2001
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
    Journal of medicinal chemistry, 2001, Jun-07, Volume: 44, Issue:12

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Dogs; Dox

2001
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
    Clinical therapeutics, 2001, Volume: 23, Issue:5

    Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comor

2001
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
    The Prostate, 2001, Jul-01, Volume: 48, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Endothelial Growth

2001
Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia.
    Urologia internationalis, 2001, Volume: 67, Issue:2

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Cholesterol; Humans; Lipoproteins; Male; Middle Aged; Pra

2001
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
    The Journal of urology, 2002, Volume: 167, Issue:4

    Topics: Adrenergic beta-Antagonists; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyper

2002
Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
    The Journal of urology, 2002, Volume: 167, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Japan; Male; Middle Aged; Muscle Cont

2002
The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle.
    The Prostate, 1992, Volume: 21, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Muscle, Smooth; Prazosin; Prostatic H

1992
A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia.
    British journal of pharmacology, 1992, Volume: 107, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Colforsin; Dihydroalprenolol; Humans; In Vitro Techniques; Isometric

1992
The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
    The Prostate, 1992, Volume: 20, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Flutamide; Humans; Male; Middle Aged;

1992
[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1992, Volume: 83, Issue:3

    Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Piperazines; Prazosin; Prostatic Hyperpla

1992
The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin.
    Military medicine, 1992, Volume: 157, Issue:7

    Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Florida; Follow-Up Studies; Hospit

1992
[Clinical effects of distigmine bromide (Ubretid), a cholinesterase inhibitor, on micturition disturbance by benign prostatic hypertrophy--comparative study of distigmine bromide and the combination of distigmine bromide and adrenergic blocker].
    Hinyokika kiyo. Acta urologica Japonica, 1992, Volume: 38, Issue:9

    Topics: Aged; Aged, 80 and over; Drug Evaluation; Drug Therapy, Combination; Humans; Male; Middle Aged; Praz

1992
[Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens].
    Archivos espanoles de urologia, 1992, Volume: 45, Issue:3

    Topics: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Plant Extracts; Prazosin; Prostatic Hyperplasia;

1992
Density and localization of alpha 1-adrenoceptors in hypertrophied prostate.
    The Journal of urology, 1990, Volume: 143, Issue:3

    Topics: Aged; Autoradiography; Humans; Male; Middle Aged; Prazosin; Prostate; Prostatic Hyperplasia; Radioli

1990
Prazosin: an evaluation of its clinical efficacy and safety in the treatment of benign prostatic hypertrophy.
    Urologia internationalis, 1990, Volume: 45 Suppl 1

    Topics: Humans; Male; Prazosin; Prostatic Hyperplasia

1990
Clinical studies on the effectiveness of prazosin HCl (Minipress tablets) in the treatment of dysuria accompanying benign prostatic hyperplasia.
    Urologia internationalis, 1990, Volume: 45 Suppl 1

    Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prazosin; Pros

1990
Effects of prazosin HCl on micturition disturbance associated with benign prostatic hypertrophy and bladder neck contracture.
    Urologia internationalis, 1990, Volume: 45 Suppl 1

    Topics: Humans; Male; Prazosin; Prostatic Hyperplasia; Urethral Obstruction; Urinary Bladder Neck Obstructio

1990
Effects of prazosin HCl on the urethral pressure profile in patients with benign prostatic hyperplasia.
    Urologia internationalis, 1990, Volume: 45 Suppl 1

    Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prazosin; Pres

1990
Effects of an alpha 1-adrenergic blocker (prazosin HCl) on micturition disturbances associated with benign prostatic hypertrophy.
    Urologia internationalis, 1990, Volume: 45 Suppl 1

    Topics: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Pressure; Prostatic Hyperplasia; Ureth

1990
The efficacy of prazosin HCl in the treatment of urinary flow obstruction due to prostatic hypertrophy.
    Urologia internationalis, 1990, Volume: 45 Suppl 1

    Topics: Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urethral Obstru

1990
[Localization of alpha 1-adrenoceptors in hypertrophic prostate].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1991, Volume: 82, Issue:1

    Topics: Aged; Autoradiography; Humans; Iodine Radioisotopes; Male; Middle Aged; Phenethylamines; Prazosin; P

1991
Alfuzosin for benign prostatic hypertrophy.
    Lancet (London, England), 1991, Jul-20, Volume: 338, Issue:8760

    Topics: Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Male; Prazosin; Prostatic Hyperp

1991
Prazosin concentration monitoring in the treatment of prostatic adenoma.
    International urology and nephrology, 1991, Volume: 23, Issue:2

    Topics: Aged; Humans; Male; Middle Aged; Monitoring, Physiologic; Prazosin; Prospective Studies; Prostatic H

1991
[3H]bunazosin, a novel selective radioligand of alpha 1 adrenoceptors in human prostates.
    The Journal of urology, 1991, Volume: 146, Issue:3

    Topics: Adrenergic alpha-Antagonists; Cell Membrane; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia

1991
[Characterization and localization of alpha 1-adrenoceptors in human prostate--with special reference to the zonal difference in receptor distribution].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1991, Volume: 82, Issue:8

    Topics: Autoradiography; Binding Sites; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Quinazoline

1991
[Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity].
    Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi, 1991, Volume: 27, Issue:3

    Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Muscle Contraction; Muscle, Smooth; Norep

1991
Alpha 2 adrenergic receptors in hyperplastic human prostate: identification and characterization using [3H] rauwolscine.
    The Journal of urology, 1986, Volume: 135, Issue:5

    Topics: Binding, Competitive; Cerebral Cortex; Clonidine; DNA; Humans; Kinetics; Male; Nordefrin; Prazosin;

1986
[Alpha adrenergic blocking agents in disorders of the bladder sphincter].
    La Revue du praticien, 1986, Jan-21, Volume: 36, Issue:5

    Topics: Adrenergic alpha-Antagonists; Adult; Female; Humans; Male; Moxisylyte; Nicergoline; Phenoxybenzamine

1986
Comparison of the alpha-adrenoceptor characteristics in human and canine prostate.
    Federation proceedings, 1986, Volume: 45, Issue:11

    Topics: Adrenergic alpha-Antagonists; Animals; Dogs; Humans; Male; Muscle Contraction; Norepinephrine; Prazo

1986
Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy.
    The Journal of pharmacology and experimental therapeutics, 1987, Volume: 242, Issue:1

    Topics: Binding, Competitive; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic

1987
The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain.
    The Journal of urology, 1988, Volume: 140, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Animals; Binding Sites; Binding, Competitive; Cerebral Cortex; D

1988
[Effect of prazosin on human prostatic adenoma tissue].
    Biulleten' eksperimental'noi biologii i meditsiny, 1988, Volume: 106, Issue:8

    Topics: Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Humans; In Vitro

1988
[Prazosin in the treatment of patients with adenoma of the prostate gland].
    Sovetskaia meditsina, 1988, Issue:9

    Topics: Humans; Male; Prazosin; Prostatic Hyperplasia

1988
Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation.
    British journal of urology, 1989, Volume: 63, Issue:5

    Topics: Adult; Aged; Humans; Male; Middle Aged; Muscle Contraction; Norepinephrine; Prazosin; Prostate; Pros

1989
Prazosin in benign prostatic hypertrophy.
    DICP : the annals of pharmacotherapy, 1989, Volume: 23, Issue:6

    Topics: Humans; Male; Prazosin; Prostatic Hyperplasia

1989
The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
    International journal of clinical pharmacology, therapy, and toxicology, 1989, Volume: 27, Issue:8

    Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Middle Aged; Prazosin; Prostatic H

1989
Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
    Arzneimittel-Forschung, 1989, Volume: 39, Issue:10

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Pilot Projects; Pr

1989
In vitro characterization of the alpha-adrenoceptors in human prostate.
    European journal of pharmacology, 1985, Jan-02, Volume: 107, Issue:2

    Topics: Adrenergic alpha-Antagonists; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; M

1985